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RESUMO 
 
 As mutações activadoras nos genes BRAF e rat sarcoma viral oncogene (RAS) e 
o rearranjo rearranged during transfection (RET/PTC) são responsáveis pela activação da 
via mitogen-activated protein kinase (MAPK) nas células tumorais da tireoide. Esta 
activação constitutiva da via de sinalização conduz a processos de proliferação e 
resistência à apoptose celulares, assim como perda de expressão de genes da tireoide, 
incluindo o NIS, cuja função da proteína é indispensável para o funcionamento da 
tireoide. Por outro lado, a activação da via phosphoinositide 3-kinase/protein kinase 
B/mammalian target of rapamycin (PI3K/Akt/mTOR) também tem um papel importante na 
transformação das células. Mutações nos seus efectores, juntamente com mutações na 
via MAPK, são responsáveis pela activação constitutiva desta via.  
A molécula mTOR, uma cinase serina/treonina, é activada pela via 
PI3K/Akt/mTOR. É constituída por dois complexos, o complexo 1 (mTORC1) e o 2 
(mTORC2). O mTORC1 participa na biogénese dos ribossomas por activação da 
ribosomal protein S6 (S6) e na tradução do ácido ribonucleico mensageiro (mRNA). Por 
sua vez, o mTORC2 participa na organização do citoesqueleto por activação da protein 
kinase Cα (PKCα), assim como na migração e sobrevivência celulares por activação da 
Akt na serina 473.  
Aproximadamente 10-15% dos carcinomas papilares da tireoide (PTC) perdem 
expressão do NIS, tornando-se indetectáveis no diagnóstico e resistentes ao tratamento 
com 131I, agravando significativamente o seu prognóstico. Estes casos merecem uma 
atenção especial, uma vez que requerem terapias alternativas. Um dos alvos nestas 
terapias é a via mTOR. 
O objectivo geral deste trabalho foi investigar a activação da via mTOR nos PTC. 
Para tal, estudámos a activação da via mTOR em duas séries, uma delas com 73 e a 
outra com 114 PTC, e avaliámos a expressão de dois marcadores moleculares da via – 
mTOR fosforilado (p-mTOR) na serina 2448 e S6 fosforilado (p-S6) na serina 235/236, o 
seu efector imediato. Para além disso, investigámos também possíveis associações entre 
esses marcadores e características moleculares e clinico-patológicas. 
Os nossos resultados mostraram que a expressão de p-mTOR tinha uma 
associação significativa com a extensão extra-tireoideia e metástases à distância, assim 
como com a persistência de doença no final do follow-up nas variantes clássicas de PTC 
(cPTC).  Este marcador estava também preferencialmente localizado na periferia e na 
frente invasiva dos tumores. Por sua vez, a expressão de p-S6 revelou ser inconsistente 
entre as duas séries, uma vez que mostrou estar associada a factores de bom 
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prognóstico numa das séries e à invasão vascular na outra. Adicionalmente, não 
encontrámos nenhuma correlação entre a expressão dos dois marcadores.  
Estes resultados sugerem que o p-mTOR é um marcador mais promissor nos 
tumores da tireoide. Confirmámos ainda a activação da via mTOR em PTC, e propomos 
que essa activação ocorra por via do mTORC2, dado as associações com características 
de agressividade e a inexistência de correlação entre a expressão de p-mTOR e p-S6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 
 XIII 
  
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 XIV 
ABSTRACT 
 
Gain-of-function mutations in BRAF and rat sarcoma viral oncogene (RAS) and 
rearranged during transfection fusion gene (RET/PTC) rearrangement are responsible for 
activation of the mitogen-activated protein kinase (MAPK) signaling pathway in thyroid 
cancer cells. Constitutive activation of this pathway leads to uncontrolled cell proliferation 
and resistance to apoptosis, as well as loss of thyroid-differentiated gene expression, 
including the gene coding for NIS, which is indispensable for thyroid function. On the other 
hand, activation of the phosphoinositide 3-kinase/protein kinase B/mammalian target of 
rapamycin (PI3K/Akt/mTOR) pathway also plays a major role in transformation of cells. 
Mutations in its effectors, along with mutations in the MAPK cascade, are responsible for 
constitutive activation of the pathway.  
mTOR, a serine/threonine kinase, is activated by the PI3K/Akt/mTOR pathway. It 
comprises mTOR complex 1 (C1), which participates in ribosomal biogenesis via 
activation of ribosomal protein S6 (S6), and messenger ribonucleic acid (mRNA) 
translation; and mTOR complex 2 (C2), which participates in cytoskeleton organization via 
activation of protein kinase Cα (PKCα), and cell migration and survival via activation of 
Akt on serine 473.  
Approximately 10-15% of papillary thyroid carcinoma (PTC) lose expression of NIS 
and become undetectable to diagnosis and resistant to treatment with 131I, which worsens 
their prognosis significantly. These cases require special attention because alternative 
treatment options are required. One of the targets in such cases is the mTOR pathway. 
The general aim of this work was to investigate the mTOR pathway activation in 
PTC. In order to do that, we studied the mTOR pathway activation in two series, one with 
73 and the other with 114 PTC, and evaluated the immune-expression of two molecular 
markers of the mTOR pathway – phosphorylated mTOR (p-mTOR) on serine 2448 and 
phosphorylated S6 (p-S6) on serine 235/236, its immediate effector. Furthermore, we 
investigated possible associations between these markers and clinico-pathological and 
molecular features.  
Our results showed p-mTOR expression to be significantly associated with 
extrathyroid extension and distant metastases, as well as persistence of disease after 
follow-up in the classical variant of PTC (cPTC). p-mTOR was also preferentially localized 
in the periphery of tumors and in their invasive front. In turn, p-S6 expression was not 
consistent between series, being associated with factors of good prognosis in one and 
with vascular invasion in the other. Furthermore, we did not find any correlation between 
p-mTOR and p-S6 expression.  
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These results suggest that p-mTOR is a more promising marker in thyroid tumors. 
Our results confirmed the activation of mTOR pathway in PTC, and suggest its activation 
to occur via mTORC2, given the associations with clearly aggressive features and the lack 
of correlation between expression of p-mTOR and p-S6.  
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 3 
INTRODUCTION 
 
 
THE THYROID GLAND 
 
1.1 Anatomical Features 
The thyroid gland (Figure 1-A), situated in the lower anterior neck in front of the 
trachea, is composed of right and left lobes, connected in the middle by an isthmus and 
encapsulated in a thin fibrous connective tissue [1]. It has an extensive lymphatic system 
network, which comprises regional lymph nodes that belong to levels I to VII (anterior 
triangle, upper jugular, middle jugular, lower jugular, posterior triangle, central 
compartment and upper mediastinal, respectively) [2]. 
The basic constitutive unit of this endocrine gland is the follicle. A single layer of 
polarized follicular epithelial cells outlines each of these follicles and colloid material is 
present in the lumen of the follicles. Normal follicles range from 50 to 500µm in size 
(200µm average). The follicular cells can vary in shape, from flat to columnar, depending 
on their degree of hormone synthesis activity, with flat follicular cells being less active than 
the columnar cells. Their nuclei are round and basally located, with diffuse chromatin. In 
the basal membrane of the follicular cells are the molecules which transport iodide (I-) into 
the follicular cells (Figure 1-B). These molecules are called the sodium/iodide symporter 
(NIS), and they uptake iodide in exchange for sodium (Na+), against a concentration and 
an electrical gradient, therefore using energy in the form of adenosine triphosphate (ATP) 
[1, 2]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Macro- and microscopic structure of the thyroid gland. A – The gland is located in the lower anterior neck 
across the front of the trachea. A single layer of follicle cells outlines each of these basic units, and colloid is present in their 
lumen. In the interfollicle space there can be seen blood vessels and a couple of C cells grouped together [4]. B – the 
sodium/iodide symporter is located in the basal membrane of the follicular cells, and is responsible for the uptake of iodide 
into the follicular cells. Adapted from Boron et al. (2012) Section VIII: The endocrine system, in Medical Physiology: A 
cellular and molecular approach. 
A B 
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Figure 2 – Hypothalamic-pituitary-thyroid axis. The levels of circulating thyroid hormones T4 and T3.are maintained by a 
negative feedback loop. The hypothalamus responds to low circulating levels of T4 and T3 by releasing TRH, which in turn 
stimulates the production of TSH by the anterior pituitary gland. TSH then stimulates the thyroid gland to synthesize T4 and 
T3. Adapted from Hill et al. (1998) Risk assessment of thyroid follicular cell tumors, Environ Health Persp. 
Also present in the thyroid parenchyma are C cells, or parafollicular cells, but they 
are not part of the follicle. They are present in small numbers, between or peripheral to 
follicular cells. C cells produce calcitonin, a hormone involved in calcium (Ca2+) and 
phosphate homeostasis [2]. 
 
1.2 Thyroid Physiology  
The thyroid is an endocrine gland, and its role in the organism is to produce 
hormones. The thyroid hormones include thyroxine (T4) and triiodothyronine (T3), whose 
precursors are constitutive part of the hormone thyroglobulin (Tg), a macromolecule 
present in the colloid structure in the follicle [3]. Hormone synthesis is very complex, 
involving not only the thyroid gland for the production of hormones, but also the central 
nervous system (CNS), which regulates their synthesis, and T4-T3 peripheral conversion. 
As a matter of fact, the thyroid is part of the hypothalamic-pituitary-thyroid (HPT) axis 
(Figure 2), which is responsible for the regulation of circulating levels of T4 and T3 by 
classical negative feedback – if T4 and T3 are circulating in low levels, the hypothalamus 
reacts by releasing thyrotropin-releasing hormone (TRH), which in turn stimulates the 
anterior pituitary gland to secrete thyroid-stimulating hormone (TSH); by interaction with 
thyroid-stimulating hormone receptor (TSHR), TSH will then stimulate the thyroid gland to 
synthesize T4 and T3, thus replenishing their levels in the circulation [4]. The TSH activity 
stimulates the cyclic adenine monophosphatase (cAMP) cascade, which is responsible for 
transcriptional and post-transcriptional regulation of Tg and thyroid peroxidase (TPO) [5].  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 
 5 
Thyroid hormones are synthesized only if iodide uptake occurs (Figure 3). Until 
then, their precursors remain inactive while bound to Tg in the colloid. The synthesis of 
thyroid hormones can be divided into 6 stages: (1) iodide trapping, (2) iodination, (3) 
conjugation, (4) endocytosis and proteolysis, and (5) secretion [6]. TSH stimulates each of 
these steps, except for the exocytosis of iodide to the colloid. If TSH is present in high 
concentrations, the rate at which hormone synthesis and release occurs is much faster 
than when TSH is in low concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Iodide trapping – in this first stage, the anterior pituitary gland secretes TSH, which 
will stimulate the activity of NIS (basolateral membrane of the follicular cells), thus 
increasing the concentration of iodide in the follicular cells. Iodide uptake occurs 
against a concentration and an electrical gradient, and its transport is coupled with 
sodium transport, therefore requiring energy and oxidative metabolism. At this point, 
the follicular cells secrete Tg into the lumen; 
(2) Iodination – iodide diffuses to the apical surface of the follicular cells, and leaves 
them presumably via pendrin, in an exocytosis vesicle formed in the follicular cells, 
entering the colloid of the follicle. Inside this vesicle, iodide is oxidized to iodine (I0) 
Figure 3 – Synthesis of thyroid hormones. TSH stimulates the synthesis of thyroid hormones, and its concentration 
affects the rates at which synthesis and release of the hormones occurs. T4 and T3 synthesis only begins when I- is co-
transported into the follicular cells by NIS, via active transport. Once inside the follicular lumen, I- is oxidized to I0 by TPO in a 
process called iodination. I0 then binds to tyrosine residues in Tg, producing DIT and MIT. The conjunction of two DIT and a 
MIT with a DIT yields T4 and T3, respectively. At this stage, they are still bound to Tg, but ready to be transported from the 
colloid to the follicular cells. Once in the follicular cells, Tg is hydrolyzed, resulting in the release of both hormones into the 
blood circulation. The hormones become ready to be transported to target cells. Adapted from Cohen-Lehman et al. (2010) 
Effects of amiodarone therapy on thyroid function, Nat Rev Endocrinol. 
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by TPO. I0 then binds to tyrosine residues of Tg, resulting in the formation of 
diiodotyrosine (DIT) and monoiodotyrosine (MIT); 
(3) Conjugation – the conjugation of iodinated tyrosine residues (DIT and MIT) results in 
the formation of T4 and T3 linked to Tg. T4 is the result of conjugation between two 
DIT molecules, and T3 is formed by a DIT molecule conjugated with a MIT 
molecule; 
(4) Endocytosis – for T4 and T3 to be able to enter circulation, iodinated Tg is 
incorporated by endocytosis in the follicular cells in the form of colloid droplets. 
These will fuse with lysosomes, so that Tg is hydrolyzed to active T4 and T3; 
(5) Secretion – finally, the free hormones are secreted into the blood circulation, where 
they bind to carrier proteins for transport to target cells. 
 
Approximately 90% of thyroid hormones are released as T4 and the remaining 10% 
as T3. Of the released T4, roughly 80% is converted by deiodinases to T3 in the liver and 
kidney (peripheral conversion), and the rest to reverse triiodothyronine (rT3). T3 is the 
more active form, being 10 times more active than T4, whereas rT3 has no significant 
biological function [1].  
Once they reach the circulation, T4 and T3 tightly bind to plasma proteins, such as 
thyroxine-binding globulin (TBG), albumin and transthyretin (TTR), and circulate mostly 
bound to proteins. As soon as they are freed from these proteins, they carry out their 
actions on the target tissues [3]. There, they are transported inside the cells either by 
membrane proteins or by diffusion and head towards the nucleus, where they bind to 
nuclear receptors, which in turn bind to chromatin regulating the expression of specific 
genes, either by inhibition or stimulation of transcription [7]. 
Thyroid hormones play a role in the homeostasis and metabolism of the organism 
as a whole, including the cardiovascular system, respiratory system, central nervous 
system, gut, muscle, skin/hair, skeleton, kidneys, bone marrow, gonads. In infants, thyroid 
hormones are especially important in brain and somatic development, whereas in adults 
they are essential for the metabolic activity. Either excess (hyperthyroidism) or deficiency 
(hypothyroidism) of thyroid hormones has a critical impact. Iodine deficiency, which results 
in thyroid hormone deficiency, is compensated by secretion of TSH, increasing the iodide 
trapping, and therefore the concentration of thyroid hormones. Contrarily, excess iodide 
generally results in inhibitory effects in the secretion of TSH (Table 1) [3, 5]. 
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Table 1 – Physiological effects of thyroid hormones in a context of hypo- and hyperthyroidism.  
 
 
Adapted from Boron et al. (2012) Section VIII: The endocrine system, in Medical Physiology: A cellular and  
molecular approach. 
 
1.3 The Sodium/iodide Symporter (NIS) 
NIS is an integral plasma membrane glycoprotein that co-transports two Na+ along 
with one iodide, a mechanism that relies on the electrochemical gradient provided by the 
Na+/potassium (K+)-adenosine triphosphatase (ATPase) pump [8].  Besides thyroid 
follicular cells, low levels of NIS expression can be detected in salivary glands, stomach, 
small intestine and lactating mammary glands, and its regulation is tissue-specific [8]. 
 
As mentioned previously, thyroid hormone production depends on the active 
transport of iodide into the follicular cells. This is a process carried out by NIS, thus 
making it a fundamental structure in the thyroid gland. Although adequate NIS function is 
important, the supply of iodide is just as essential for the synthesis of T4 and T3 [9]. When 
thyroid function is normal, the iodide trapping mechanism is responsible for the 
accumulation of iodide, which is 30 to 60-fold more concentrated in the follicular cells than 
in the plasma [10].  
NIS expression and function regulation (Figure 4) are carried out by several 
molecules and pathways, at the transcriptional and post-transcriptional levels [11]. The 
Parameter 
Low level of thyroid hormones  
(Hypothyroid) 
High level of thyroid hormones 
(Hyperthyroid) 
Basal metabolic rate ↓ ↑ 
Carbohydrate 
metabolism 
↓ Gluconeogenesis 
↓ Glucogenolysis 
Normal serum [glucose] 
↑ Gluconeogenesis 
↑ Glucogenolysis 
Normal serum [glucose] 
Protein metabolism 
↓ Synthesis 
↓ Proteolysis 
↑ Synthesis 
↑ Proteolysis 
Muscle wasting 
Lipid metabolism 
↓ Lipogenesis 
↓ Lipolysis 
↑ Serum [cholesterol] 
↑ Lipogenesis 
↑ Lipolysis 
↓ Serum [cholesterol] 
Thermogenesis ↓ ↑ 
Autonomic nervous 
system 
Normal levels of serum catecholamines 
↑ Expression of β adrenoreceptors (increased 
sensitivity to catecholamines, which remain at 
normal levels) 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 8 
primary hormonal regulator is TSH, which exerts its function via stimulation of TSHR, 
activating the TSH-TSHR-cAMP-protein kinase A (PKA) signaling pathway [12, 13]. The 
TSH-TSHR-cAMP-PKA signaling pathway has long been studied as a regulatory pathway 
for thyroid differentiation and proliferation both PKA-dependent and –independent [14]. 
Overall, TSH is a positive regulator, as it increases iodide uptake and accumulation into 
the follicular cells, which is mediated by NIS, in a protein synthesis-dependent manner 
[15]. This mechanism, which was shown in both in vitro and in vivo models, demonstrated 
that increased iodide transport into thyroid cells was a result of positive regulation of NIS 
[16, 17]. Post-transcriptionally, NIS activity was shown to be modulated by modifications 
at the protein level, namely the phosphorylation patterns, induced by TSH, which are 
distinct from those in the absence of TSH [18], suggesting an involvement in NIS 
subcellular distribution. Besides this hormonal control, iodide itself is considered to be one 
of the main regulators of NIS function, dubbing as a homeostatic regulator of thyroid 
hormone synthesis. In 1948, Wolff and Chaikoff [19] demonstrated in rats that high doses 
of iodide caused a decrease in thyroid function. They stated that if a critically high level of 
organic iodide in the plasma was reached, an inhibitory effect in the organic binding of 
iodide would be observed; this mechanism is known as the acute Wolff-Chaikoff effect. 
Furthermore, they showed that when plasma organic iodide went down to a normal basal 
level, the effect would be reversed, and iodide organification restored. This phenomenon 
can be explained in light of an intrinsic autoregulatory mechanism, in which the thyroid 
protects itself from high doses of iodide while at the same time providing enough iodide for 
hormone synthesis.  
On the contrary, cytokines and growth factors have been shown to exert a 
negative regulation on NIS, via activation of phosphoinositide 3-kinase/protein kinase 
B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway [14, 20]. This 
pathway seems to counterbalance the activity of the TSH-TSHR-cAMP-PKA pathway, by 
downregulating NIS expression. Tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and 
interleukin-1α (IL-1α) have been implicated in both the inhibition of NIS messenger 
ribonucleic acid (mRNA) expression and TSH-induced NIS expression in FRTL-5 cells 
[20-22], whereas insulin growth factor-1 (IGF-1) was associated only with the former [20]. 
Similarly, transforming growth factor-β1 (TGF-β1) showed a decrease in TSH-induced NIS 
expression and TSH-induced iodide uptake [22], in addition to reducing Na+/K+-ATPase 
pump activity [23]. Moreover, Tg was shown to suppress NIS mRNA levels and of some 
thyroid-specific genes, suggesting that Tg acts as a negative feedback regulator, 
counteracting TSH [24]. This hypothesis was corroborated by a study from the same 
authors that showed that Tg significantly suppressed TSH-induced NIS promoter activity, 
NIS protein and NIS-dependent iodide uptake into the follicular cells [25].  
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THE BASICS OF THYROID CANCER  
 
2.1 Epidemiology 
  Thyroid cancer (TC) is the most common of endocrine malignancies and accounts 
for 1% of all cancers, having an incidence higher in women than in men, with a 3:1 ratio 
[26]. Overall, the incidence has been gradually increasing at a rate of about 6% [27]. 
Mortality rates have remained more or less stable over the years, with a reported 0.5 
cases per 100 000 individuals, although a slight increase has been noted, predominantly 
in men (+1,6% annual percent change in men versus +0,9% annual percent change in 
women) [28, 29]. If we do an analysis by histological type, papillary thyroid cancer (PTC) 
is the most common (70-80%), followed by follicular thyroid cancer (FTC) (10-15%) and 
then undifferentiated thyroid cancers (<5%) [30].The 10-year survival rate has increased 
and is now at about 93% in PTC and 85% in FTC. In undifferentiated anaplastic thyroid 
carcinoma (ATC) the 10-year survival rate is approximately 14% [31].  
In Portugal, the same trends can be observed. In the North region, where this work 
took place, the Registo Oncológico Regional do Norte (RORENO) has revealed the 
Figure 4 – Signaling pathways involved in NIS regulation. Upregulation of NIS is carried out by TSH via TSH-TSHR-
cAMP-PKA pathway, which can be dependent or independent of PKA. On the other hand, downregulation of NIS expression 
occurs via PI3K/AKT/mTOR signaling pathway and by molecules such as TNF-α, IFN-γ, IL-1α, IGF-1 and TGF-β1. Adapted 
from Riesco-Eizaguirre et al. (2006) A perspective view of sodium iodide symporter research and its clinical implications, Eur 
J Endocrinol. 
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incidence of thyroid cancer to be 21.2 cases per 100 000 individuals, and the second 
most common cancer in women (34.5 cases per 100 000 individuals, which represents 
11.8% of all cancers) [32]. Overall mortality rate is at 0.9 per 100 000 individuals, with a 
slight increase in women [33]. The 5-year survival rate is at 97.9%, and lower in men [34]. 
All of this data is in accordance to the worldwide incidence and mortality rates. 
 
 Over the years, the normal evolution of cancers dictates an increase in incidence, 
mainly because of the growing population and extended life expectancy, as well as tumor 
etiology itself, and thyroid cancer is no exception. However, it should be noted that this 
increase is happening in PTC, given that it is the main histologic subtype, while the other 
types of thyroid cancer have not been substantially affected [27]. Nowadays, 
overdiagnosis also accounts for this trend, which does not reflect a real increase in the 
disease, since mortality rates are not necessarily accompanying this tendency [28]. 
O’Grady et al. [35] performed a retrospective study in the United States comprised of 
individuals who were diagnosed between 1981 and 2011, and estimated that 
overdiagnosis resulted in 82 000 cases of PTC, that most likely would not have resulted in 
clinical symptoms, in the year of 2011. The authors estimated that the percentage of 
diagnosed cases attributable to overdiagnosis in men aged 20-49 and +50 years, were 
4% and 42%, respectively, and in women aged 29-40 and 50+ years, 47% and 61%, 
respectively. Similarly, Korean researchers have documented a 15-fold increase in thyroid 
cancer in the past two decades, which they concluded was due to overdiagnosis [36]. A 
similar tendency has been observed throughout Europe [27], including Portugal, in which 
an estimate of an incidence rate of 28.6 per 100 000 individuals should be met in 2020 
[37]. 
 The primary cause for this problem is the improvement in medical imaging 
detection by technologies such as magnetic resonance imaging (MRI), computed 
tomography (CT), ultrasonography and nuclear medicine. This means that smaller tumors 
(<1cm) with irrelevant clinical significance are being diagnosed, resulting in overtreatment 
and putting patients at risk for complications from the invasive procedures, otherwise 
avoidable [38, 39].  
 
There are several risk factors associated with the development of thyroid cancer. 
The most well-studied cause is exposure to ionizing radiation, particularly during 
childhood. Studies have concluded that there is a significant dose-response risk 
association for exposure and that radiation-induced thyroid cancer has an inverse relation 
with age at exposure and a direct relation with background iodine deficiency [40]. Genetic 
susceptibility is also associated with the risk of developing thyroid cancer. A few studies 
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have revealed an increased relative risk when thyroid carcinoma was diagnosed in direct 
relatives of TC patients, especially in first-degree relatives [41, 42]. Benign thyroid 
conditions, such as goiter, benign nodules/ adenomas and hyperthyroidism, have been 
shown to be the most important factor as a risk to develop TC [43]. This relationship is 
stronger in men, although these conditions are more common in women [44]. Hormonal 
and reproductive factors are weakly associated with the risk of developing thyroid cancer, 
but deserve attention since women are 3 times more likely than men to develop thyroid 
cancer [45]. Among dietary risk factors, iodine is by far the most important, considering 
thyroid function depends on it. Iodine deficiency is associated with FTC, whereas iodine 
sufficiency is associated with PTC [46]. Overall, as a result of iodine deficiency, TSH 
secretion is increased, suggesting this overstimulation by TSH as the mechanism behind 
the association [47]. More controversially, one study reported bigger height and higher 
body mass index to have an influence by increasing the risk of differentiated thyroid 
carcinoma (DTC) [48], whereas a different study found no associations [49]. These factors 
may suggest a potential influence of growth factors and hormones during development of 
the body.   
 
2.2 Disease Presentation and Management 
 Thyroid carcinomas can arise from thyroid follicular cells, which represent the 
majority of cancers, or from parafollicular cells. The former originate PTC, FTC, poorly 
differentiated thyroid carcinoma (PDTC) and ATC, and the latter originates medullary 
thyroid carcinoma (MTC) [50]. PDTC and ATC can develop de novo or arise from a 
process of dedifferentiation of pre-existing PTC and FTC [51].  
Thyroid tumors usually present with a single nodule, and diagnosis is made mainly 
by cytological examination of fine needle aspirate [52]. These tumors are generally slow 
growing, although they can metastasize in the regional lymph nodes, but also in the lungs, 
bone, and occasionally the brain, via hematogenous dissemination. In general, primary 
treatment consists of total thyroidectomy for most cases of DTC, although tumors less 
than 1 centimeter (cm) in diameter can be treated by unilateral lobectomy [53]. The 
decision to perform a total thyroidectomy is made based on 3 rationales: 60-85% of PTC 
cases present foci in both lobes [54], 5-10% of PTC cases recur after unilateral surgery in 
the contralateral lobe [55], and effectiveness of radioiodine ablative treatment is higher 
when resection is total, therefore increasing the sensitivity and specificity of serum Tg as a 
tumor marker [53]. Given the particularity of the thyroid gland, it is possible to take 
advantage of the iodide uptake to aid in a therapy setting. Therefore, postoperative care 
consists of adjuvant ablative therapy with radioiodine (131I), which is chemically identical to 
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the non-radioactive form, to eliminate any thyroid remnants, and radioiodine treatment for 
residual disease and metastases. When the follicular cells uptake 131I and it concentrates 
in the cells, the radionuclide undergoes β decay, resulting in a high-energy release, which 
is responsible for the cytotoxic effects. γ rays are also released and used for surveillance 
scanning procedures, given that they are detectable. As usual, there are exceptions: 
tumors less than 1 cm are not given radioiodine ablation, unless evidence of extrathyroid 
extension or metastases exists [53]. Before radioiodine ablation, it is important that the 
serum levels of TSH are sufficiently elevated to ensure that NIS expression is increased to 
optimize 131I uptake. For that purpose, withdrawal of thyroid hormone or use of 
recombinant human TSH (rhTSH) is advised to optimize 131I uptake before patients begin 
therapy [56].  
Follow-up monitoring consists of whole body scanning with radioiodine every 6-12 
months after initial ablation, and more frequently if there is an indication of recurrent 
disease. Locoregional metastases can be identified by ultrasonography, as well as 
recurring tumors measuring several millimeters in diameter [57]. Metastatic disease 
should be confirmed with a fine needle aspiration-assisted ultrasonography [58]. 
Ultrasonography should also be used in the routine monitoring of patients with 
extrathyroid extension and locoregional nodal metastases. Serum Tg levels measurement 
is also recommended to aid in the detection of recurrent and metastatic disease [59].  
 
2.3 Genetic Alterations  
 Treatment of DTC is standardized, but tumor response is not. This variability 
comes from tumor heterogeneity, such as histological type, stage, presence of 
metastases, molecular and genetic alterations, and ability to trap iodine, as well as patient 
age and gender. All of these factors contribute to the aggressiveness of the tumor, and 
consequently response to therapy. Knowing the genetic and molecular mechanisms 
through which these tumors develop has brought insight into how treatment can be 
modeled to each case. In this subchapter, genetic alterations in thyroid cancer will be 
discussed to outline the importance they have on the clinical course of the disease.  
  Similar to other cancers, thyroid cancer emerges from an accumulation of genetic 
mutations, which also dictate how the tumor will progress. In the case of thyroid cancer, 
there are critical genes that frequently undergo mutation, and thus enable characterization 
of the tumor (Figure 5).  
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BRAF Mutations 
The BRAF gene encodes for BRAF protein, a member of the rapidly accelerated 
fibrosarcoma (RAF) protein family, which are intracellular elements of the mitogen-
activated protein kinase (MAPK) pathway. In this cascade, rat sarcoma viral oncogene 
(RAS) binds and activates BRAF, which results in phosphorylation and subsequent 
activation of mitogen/extracellular signal-regulated kinase (MEK), followed by activation of 
extracellular signal-regulated kinases (ERK) [60]. The BRAF protein is important in cell 
proliferation, differentiation and apoptosis.  
The most frequent mutation that occurs in this gene is the substitution of valine to 
glutamate at codon 600 (BRAF V600E), which is an activating point mutation. This 
mutation leads to constitutive activation of BRAF, resulting in induction of the MAPK 
signaling pathway [61]. BRAF V600E occurs in approximately 45% of PTC, being more 
common in the classic (45%) and tall cell variants (80-100%), and less in the follicular 
variant (15%) [51].  
BRAF V600E is associated with an overall poor clinical prognosis, including 
presence of extrathyroid extension and lymph node metastases, as well as a high rate of 
tumor recurrence [62] due to treatment failure because of a deficient NIS targeting to the 
Figure 5 – Genetic events of thyroid cancer and the effect on the MAPK signaling pathway. Mutations of RAS, BRAF, 
TERT promoter and the rearrangements RET/PTC and PAX8/PPARγ are all genetic events that occur in the pathogenesis of 
thyroid cancer. RAS and BRAF mutations and RET/PTC rearrangement will result in activation of the MAPK signaling 
pathway, ultimately leading to transcription of genes involved in tumor cell differentiation, proliferation and survival. 
Furthermore, RAS mutation and RET/PTC rearrangement also lead to activation of the PI3K/Akt/mTOR signaling pathway 
(not pictured). TERT promoter mutation and the PAX8/PPARγ rearrangement do not participate in the activation of this 
cascade, but exert their functions through other mechanisms. The PAX8/PPARγ rearrangement directly inhibits PPARγ 
protein, located in the nucleus.  Adapted from Nikiforov et al. (2011) Molecular genetics and diagnosis of thyroid cancer, Nat 
Rev Endocrinol. 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 14 
membrane [63]. Evidence suggests this mutation to be an early event in tumorigenesis 
[60]. 
 
RAS Mutations 
 The RAS genes, which comprise neuroblastoma rat sarcoma viral oncogene 
homolog (NRAS), Harvey rat sarcoma viral oncogene homolog (HRAS) and Kirsten rat 
sarcoma viral oncogene homolog (KRAS), encode G-proteins located at the inner surface 
of the cell membrane, and are responsible for intracellular signal transduction. In a normal 
setting, RAS is bound to guanosine diphosphate (GDP) in its inactive state. Once it 
becomes active, GDP is released and RAS binds to guanosine triphosphate (GTP), 
activating the MAPK and PI3K/Akt/mTOR signaling pathways. This active state in which 
the complex RAS-GTP is formed is transient, though, and RAS quickly becomes inactive 
again due to its guanosine triphosphatase (GTPase) activity and cytoplasmic GTPase-
activating proteins [64]. 
 When a point mutation occurs in a discrete domain, it can have one of two 
outcomes – increased affinity for GTP, due to mutations in codons 12 and 13 (KRAS), or 
inactivation of the intrinsic GTPase, due to mutations in codon 61 (NRAS). All of these 
mutations switch on the active state of the gene permanently, and consequently activate 
constitutively the downstream signaling pathways.  
RAS mutations are more frequent in FTC (30-45%), whereas in PTC they are 
rather infrequent (10%) and are almost always present in the follicular variant of PTC 
(fvPTC) (30-45%) [60]. They are associated with more aggressive behavior in FTC (tumor 
dedifferentiation and less favorable prognosis) [65], but correlated with more frequent 
encapsulation, less prominent nuclear features and low rate of lymph node metastases in 
PTC [66]. However, RAS mutations are not specific for malignant lesions, as they also 
occur in follicular thyroid adenomas (FTA) [67]. 
 
TERT Promoter Mutations 
 Telomerase is responsible for maintaining the genomic integrity of cells. The 
catalytic subunit responsible for this is called the telomerase reverse transcriptase 
(TERT). The TERT gene encodes this protein that, together with an integral RNA 
component, is responsible for telomere elongation [68]. In normal cells, TERT is 
repressed in somatic cells, and in a context of cellular transformation this protein has an 
increased expression, due to mutations in the promoter region of the gene. 
 TERT promoter mutations occur in two hotspot positions – the -124 and -146 
upstream from the ATG start site. In the former, there is a guanine (G) to adenine (A) 
substitution, and in the latter there can be a substitution of a G to A or cytosine (C) to 
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thymine (T) [69]. These mutations create a sequence that harbors a consensus binding 
site (GGAA) for E26 transformation-specific (ETS) transcription factors, which lead to an 
increase in expression of TERT [70]. 
 TERT promoter mutations are present only in malignant thyroid lesions. In 
differentiated tumors, the majority is in FTC (17.1%) followed by PTC (7.5%). The lesions 
with the highest percentage of these mutations are PDTC (29%) and ATC (33.3%) [71]. 
The -124 G>A mutation is the most common of the two. In DTC, the mutations are 
associated with distant metastases, worse response to treatment and poor outcome, 
including decreased survival [71]. 
 
RET/PTC Rearrangement 
Rearranged during transfection (RET) is a proto-oncogene that encodes a tyrosine 
kinase cell membrane receptor that transduces signals for cell growth and differentiation. 
In follicular thyroid cells, this gene can be activated by a chromosomal rearrangement with 
a partner gene, which results in a RET/PTC fusion gene [60].  
The most frequent types of rearrangement are the RET/PTC1 (60-70%) and 
RET/PTC3 (20-30%), but all of the fusion genes have the intact tyrosine kinase domain of 
RET receptor. The rearrangement enables the chimeric protein to activate the MAPK 
cascade, promoting and contributing to tumorigenesis [64]. More recent evidence with 
FRTL-5 cell line points to the activation of the PI3K/Akt/mTOR signaling pathway as well 
[72].  
The rearrangement is associated with younger age and lymph node metastases in 
PTC [66]. Our group has also reported a significant association between RET/PTC 
rearrangements and FTC [73].  
  
PAX8/PPARγ Rearrangement 
 The paired box 8 (PAX8) is a gene that belongs to the PAX family genes and 
codes for the thyroid-specific paired domain transcription factor, which means that it is 
involved in expression of thyroid-specific genes [64]. The gene is a target for 
rearrangement with the peroxisome proliferator-activated receptor γ (PPARγ), which 
encodes nuclear receptors, resulting in the PAX8/PPARγ fusion gene. The rearrangement 
is a result of the chromosomal translocation t(2;3)(q13;p25) [74].   
The mechanism by which the fusion gene leads to cell transformation is not 
established, but it is known that PAX8/PPARγ leads to a strong overexpression of the 
chimeric protein, inhibiting the tumor suppressor activity of PPARγ [51].  
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Figure 6 – MAPK signaling pathway activation. Activation of this pathway occurs through binding of molecules, such as 
growth factors, to their receptors in the cytoplasmic membrane. This activates RAS, initiating the signaling cascade that 
culminates with activation by phosphorylation of ERK1/2. This protein complex is responsible for activating genes in the 
nucleus that are involved in differentiation, proliferation and survival. Adapted from Oikonomou et al. (2014) BRAF vs RAS 
oncogenes: are mutations of the same pathway equal? Differential signaling and therapeutic implications, Oncotarget.  
The frequency of the rearrangement is approximately 30-35% for FTC and lower in 
Hürthle cell carcinomas, and fvPTC has a frequency of 1-5% [75]. Evidence indicates that 
this rearrangement is associated with younger age, vascular invasion and smaller tumors 
[76]. 
 
 
SIGNALING PATHWAYS IN THYROID CANCER 
 
3.1 MAPK Signaling Pathway 
 The activation of MAPK cascade (Figure 6) begins when growth factors, hormones 
or chemokines bind to their respective tyrosine kinase receptors (RTK), like the epidermal 
growth factor receptor (EGFR), on the cell membrane. Upon binding, the extracellular 
domain of the RTK dimerizes and induces kinase activity in the cytoplasmic domain via 
phosphorylation of tyrosine residues. The receptor is now able to provide docking sites for 
proteins, such as the growth factor receptor-bound protein 2 (GRB2). The binding of 
GRB2 induces recruitment of an effector protein, which can be the guanine-nucleotide 
exchange factor son of sevenless (SOS), responsible for the nucleotide exchange of GDP 
to GTP. This exchange occurs while GDP/GTP is bound to RAS, in the cytoplasm. From 
here on, RAS is activated, giving rise to a series of activation of other effector proteins 
(RAF, MEK, ERK), culminating in activation genes encoding for transcription factors 
associated with cell differentiation, proliferation and survival [77]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 
 17 
The gain-of-function mutations in BRAF and RAS and RET/PTC rearrangement 
are responsible for activation of the MAPK signaling pathway in cancer cells. Constitutive 
activation of this pathway leads to uncontrolled cell proliferation and resistance to 
apoptosis (or cell survival), contributors to transformation and progression of cancer, as 
well as loss of thyroid-differentiated gene expression, including NIS, TPO and Tg, via 
methylation of their promoter [78, 79]. The tumorigenic expression of this cascade is 
amplified by secondary molecular alterations such as genome-wide hypermethylation and 
hypomethylation [80]. The activation of MAPK pathway ultimately leads to upregulation of 
several oncogenic genes encoding for proteins such as chemokines [81], vascular 
endothelial growth factor (VEGF) [82], nuclear factor-κB (NF-κB) [83], matrix 
metalloproteinases (MMPs) [84], vimentin [85], hypoxia-inducible factor-1α (HIF-1α) [86] 
and TGF-β1 [87], which are all known to play a role in tumorigenesis by inducing tumor 
cell proliferation, growth, migration and survival and tumor angiogenesis, invasion and 
metastasis. 
 
3.2 PI3K/AkT/mTOR Signaling Pathway  
 PI3Ks are a family of lipid kinases that phosphorylate the 3’-hydroxyl group of 
phosphatidylinositol (PtdIns) on the plasma membrane. There are different isoforms that 
act in several physiological processes such as inflammation, metabolism, migration and 
survival, as well as cancer progression, and can be differentiated by their structure, lipid 
substrate specificity and action mechanism [88].  
Class I PI3Ks are the best characterized and most important in cancer. It has two 
subunits that are activated by RTKs upon binding – p85 and p110. Activation of this 
pathway occurs in the same way as activation of MAPK pathway – binding of growth 
factors or chemokines to their RTKs. This binding is responsible for the activation of RAS, 
which regulates the activation of PI3K, much like it does in the MAPK pathway to BRAF. 
The p110 subunit of PI3K is also activated, and phosphorylates phosphatidylinositol-4,5-
biphosphate (PIP2) to produce phosphatidylinositol-3,4,5-triphosphate (PIP3). At this point, 
PIP3 can translocate Akt to the cell membrane, where it becomes active by 
phosphorylation. Akt activates downstream effectors, among which is mTOR, in order to 
target molecules that regulate cell functions [89]. A schematic representation of pathway 
is pictured in Figure 7. 
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Figure 7 – PI3K/Akt/mTOR signaling pathway activation. Activation of PI3K/Akt/mTOR pathway occurs by 
phosphorylation of RAS in the MAPK pathway. This causes activation of effectors PIP2 and 3, which in turn activates Akt. 
Akt activates its downstream effectors, including mTOR, in order to target genes in the nucleus responsible for ribosomal 
biogenesis and mRNA translation, as well as cytoskeleton organization. PTEN is the negative regulator of this cascade, and 
it exerts its function at the PIP2 level. Adapted from Oikonomou et al. (2014) BRAF vs RAS oncogenes: are mutations of the 
same pathway equal? Differential signaling and therapeutic implications, Oncotarget. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
The protein phosphatase and tensin homolog deleted on chromosome ten (PTEN) 
is also involved in this cascade by exerting a negative regulation through 
dephosphorylation of PIP3, therefore terminating the signal of the cascade [90]. 
  
Genetic Events Contributing to PI3K/Akt/mTOR Pathway Activation 
Genetic alterations in genes coding for the proteins involved in the PI3K/Akt/mTOR 
pathway have serious implications in the development of cancer, and in conjunction with 
BRAF mutations, the alterations in the pathway effectors have been shown to increase the 
aggressiveness of tumors [91]. Wu et al. suggested that amplification of a gene coding for 
a catalytic subunit of PI3K, largely present in differentiated thyroid cancer tissue and in 
thyroid cancer cell lines, could be an activating mechanism of the PI3K/Akt/mTOR 
signaling pathway in thyroid cancer [92]. Furthermore, in a study using thyroid cancer cells 
lines and tissues, it was shown that levels of phosphorylated total Akt were increased in 
FTC [93]. Alterations in the genes Akt1, 2 and 3 have been reported in different cancers 
[77, 94]. Mutation of Akt1 has been identified in breast, colorectal and ovarian carcinomas, 
and amplification of the gene in prostatic carcinomas. Akt2 mutations were reported in 
breast carcinomas and its amplification in pancreatic, ovarian and breast carcinomas. 
Akt3 mutation has been reported in melanomas and the amplification in breast 
carcinomas. The mutations in these genes cause constitutive activation of its protein 
downstream effectors, which results in evasion of apoptosis and transformation of cells 
contributing to tumor invasion and metastasis [95]. 
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Gain-of-function mutations in RAS and loss-of-function mutations in PTEN are also 
contributors to the activation of PI3K/Akt/mTOR pathway in thyroid cancer. PTEN is 
mutated in hereditary (Cowden Syndrome) and sporadic thyroid cancers [96] and its 
mutations are most likely associated with constitutive activation of Akt [95]. 
 
mTOR: The Protein and the Pathway 
 mTOR is a serine/threonine kinase that belongs to the PI3K-related protein kinase 
(PIKK) family [97], and the gene is located on chromosome 1, 1p36.2 [98]. In eukaryotic 
cells, mTOR comprises two complexes – mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). mTORC1 is rapamycin-sensitive, and consists of mTOR, 
regulatory-associated protein of mTOR (raptor), mammalian lethal with sec13 protein 8 
(mLST8) and the negative regulators proline-rich Akt substrate of 40kDa (PRAS40) and 
DEP domain-containing mTOR-interacting protein (deptor); its activity is regulated by 
raptor. On the other hand, mTORC2 is rapamycin-insensitive, and consists of mTOR, 
rapamycin-insensitive companion of mTOR (rictor), mLST8, mammalian stress-activated 
protein kinase interacting protein 1 (mSin1), protein observed with rictor (protor), heat 
shock protein 70 (Hsp70) and the negative regulator deptor; this complex is regulated by 
rictor [99] (Figure 8).   
 
 
 
 
 
 
 mTORC1 is activated by the PI3K/Akt/mTOR pathway and is inhibited by the 
tuberous sclerosis protein 1/2 complex (TSC1/TSC2). It is responsible for the regulation of 
ribosomal biogenesis by phosphorylation and activation of p70 ribosomal S6 kinase 
(S6K), which then activates ribosomal protein S6 (S6). Its other role is to regulate protein 
synthesis by phosphorylation and inhibition of eukaryotic translation initiation factor 4E-
binding protein 1 (eIF4E/4EBP1), which causes its release to bind to other proteins in 
order to initiate mRNA translation [100]. mTORC2 is regulated by rictor. Its activation 
depends on the presence of growth factors, and once active, it phosphorylates Akt on 
serine (Ser) 473, via Sin1, while phosphoinositide-dependent kinase 1 (PDK1) 
Figure 8 – The mTOR protein. mTOR is part of two complexes – complex 1 (mTORC1) consists of its main regulator 
raptor and three other molecules, mLST8 and the negative regulators deptor and PRAS40. This complex is responsible 
for regulating ribosomal biogenesis and mRNA translation; the complex 2 (mTORC2) is comprised of its main regulator 
rictor and the molecules mLST8, mSin1, Hsp70 protor, as well as the negative regulator deptor. mTORC2 is 
responsible for regulating cytoskeleton organization as well as cellular metabolism. Adapted from Cargnello et al. 
(2015) The expanding role of mTOR in cancer cell growth and proliferation, Mutagenesis. 
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Figure 9 – PI3K/Akt/mTOR signaling pathway. Growth factors, amino acids and ATP and O2 levels, which are responsible 
for starting this cascade, will activate PI3K (also activated by RAS in the MAPK pathway). In turn, Akt is phosphorylated by 
mTORC2, disrupting the TSC1/TSC2 complex, and activates mTORC1. This complex phosphorylates and activates S6K1 
and phosphorylates and inhibits the complex eIF4E/4EBP1. S6K1 phosphorylates S6, which is involved in ribosome 
biogenesis. On the other hand, eIF4E is released from its complex, and binds to other molecules such as eIF4A and eIF4A, 
in order to initiate mRNA translation. A number of other cellular processes are regulated by this pathway – protein synthesis, 
cellular growth, proliferation and survival. Adapted from Populo et al. (2012) The mTOR pathway signaling in cancer, Int J 
Mol Sci.  
phosphorylates it on Threonine (Thr) 308. Akt is involved in cell survival and migration. 
Protein kinase Cα (PKCα) is also phosphorylated by mTORC2 to regulate activity of small 
GTPases in order to act on cytoskeleton organization [101]. Sin1 is also responsible for 
targeting mTORC2 to the membrane. 
 
This pathway (Figure 9) is activated and regulated by several growth factors, such 
as epidermal growth factor (EGF), IGF-1, platelet-derived growth factor (PDGF) and 
VEGF, amino acids and ATP and oxygen (O2) levels, as well as the MAPK pathway [102]. 
Signaling through mTOR modulates several downstream pathways that regulate cell-cycle 
progression, translation initiation, transcriptional stress responses, protein stability and 
survival of cells [103]. While we know that mTORC1 has several regulators, regulation of 
its counterpart mTORC2 is largely unknown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One of the hormones that regulates mTORC1 is insulin. It is responsible for the 
activation of class I PI3Ks and the downstream effector Akt, which when active reverses 
the inhibitory effect that TSC1/TSC2 has on the cascade [104]. Amino acids present in 
nutrients also exert a positive regulation on mTORC1 by inducing S6K and 4E-BP1 
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phosphorylation [105]. ATP is equally important – under ATP deprivation, mTORC1 in 
inhibited by TSC2 in order to prevent cell apoptosis; conversely, under high levels of 
energy, Akt is phosphorylated and activates mTORC1 [106]. Oxygen deprivation is 
another negative regulator of mTORC1 – in response to energy stress, the hypoxia-
inducible gene regulated in development and deoxyribonucleic acid (DNA) damage 
responses 1 (REDD1) is induced, therefore inhibiting mTORC1 and cell growth [107]. 
Additionally, MAPK pathway can also activate mTORC1, and it does so by activating 
ERK1/2, which results in dissociation of the TSC1/TSC2 complex, and thus activation of 
mTORC1 [108]. 
   
3.3 Interaction between the PI3K/Akt/mTOR and MAPK Pathways  
 Between PI3K/Akt/mTOR and MAPK pathways there is an interplay in which a 
downstream member of one pathway is directly involved in the activation/inhibition of an 
upstream member of the other (Figure 10). This means that both pathways can activate or 
inhibit each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Diagram of the interactions between the MAPK and PI3K/Akt/mTOR pathways. The first interaction 
occurring between these pathways is via RAS and PI3K, which results in activation of the PI3K pathway. At the TSC1/TSC2 
level in the PI3K/Akt/mTOR pathway, ERK1/2 can inactivate that complex, enabling the progression of the PI3K/Akt/mTOR 
cascade. Raptor can also be activated by both ERK1/2 and RSK, which also dissociate the TSC1/TSC2 complex. Adapted 
from De Luca et al. (2012) The RAS/RAF/MEK/ERK and the PI3K/Akt signaling pathways: role in cancer pathogenesis and 
implications for therapeutic approaches, Expert Opin Ther Targets.  
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 This crosstalk seems to be important to promote and maintain growth and survival 
of transformed cells, although it is dependent of context. At the very beginning of the 
cascade, there is an important interaction, which happens between RAS and PI3K. 
Activation of RAS can have a positive effect in the other pathway, seeing that RAS is also 
responsible for activating PI3K, and thus initiating this signaling cascade. Besides, the 
MAPK pathway can also control the PI3K/Akt/mTOR pathway at the TSC1/TSC2 level, by 
inactivating the complex via ERK1/2 activity. This results in dissociation of the complex, 
which we already know enables the progression of PI3K/Akt/mTOR pathway [108]. Lastly, 
raptor can also be activated by both ERK1/2 and p90 ribosomal kinase (RSK) (which also 
dissociates the TSC1/TSC2 complex) [109, 110]. 
 Although there are plenty of interactions between pathways, they mostly occur in 
the early stages of the PI3K/Akt/mTOR pathway and go down until S6K. This means that 
S6 can only be activated by mTOR (via S6K).  
  
  3.4 Impaired Iodide Metabolism in Cancer 
The ability of thyroid cells to uptake iodide from the bloodstream through NIS 
makes possible an efficient targeted therapy in thyroid cancer. In this context, 131I is 
administrated systemically and captured by thyroid cells, causing their death. 
Unfortunately, 10-15% of PTC lose NIS expression/functionality, becoming undetectable 
to diagnosis and resistant to 131I treatment, which worsens significantly their prognosis [9].  
The molecular mechanisms underlying NIS underexpression are not fully understood. 
However, it is well established that tumors harboring BRAFV600E mutation have loss of NIS 
expression [8]. It is also described that mTOR pathway activation impairs NIS expression 
[111] and that treatment of thyroid cancer cell lines with rapamycin is able to restore NIS 
expression and 131I uptake [112].  
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AIMS OF THE STUDY 
   
The general aim of this work was to investigate the mTOR pathway activation in 
PTC.  
In order to do that, we evaluated the immune-expression of two molecular markers  
of mTOR pathway – phosphorylated mTOR and phosphorylated S6, its immediate 
effector. Furthermore, we investigated possible associations between those markers and 
clinico-pathological and molecular features.  
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METHODOLOGY 
 
MATERIAL 
   
1.1 Samples 
Tumor samples were obtained from Centro Hospitalar de São João (CHSJ) and 
Centro Hospitalar e Universitário de Coimbra (CHUC), comprising two different series, 
with approval from the ethic committee of both institutions. CHSJ series consists of 
consecutive cases and CHUC series of cases selected according to outcomes. From now 
on, CHSJ series will be designated as Series 1 and CHUC as Series 2.  
The samples were stored at Instituto de Patologia e Imunologia da Universidade 
do Porto (Ipatimup) as formalin-fixed paraffin-embedded (FFPE) tissue samples. 
Diagnosis and clinicopathological data were obtained from CHSJ and CHUC medical 
records of each patient. Clinicopathological data was reviewed before any statistical 
analysis was performed and an experienced certified pathologist reviewed the diagnosis 
of each case before the beginning of this work. Series 1 is comprised of 90 patients and 
Series 2 of 127 patients, each case with one sample.  
The clinico-pathological variables studied, both series combined, were gender, 
age, lymph node metastases (yes/no), distant metastases (yes/no), tumor size (<2cm, 
≥2cm), tumor capsule (yes/no), tumor capsule invasion (yes/no), vascular invasion 
(yes/no), tumor margins (well defined/infiltrative), thyroid capsule invasion (yes/no), 
extrathyroid extension (yes/no), multifocality (single/multiple), lymphocytic infiltrate 
(yes/no), staging (I, II, III, IVa and IVc), BRAF mutation (V600E), NRAS mutation (Q61R, 
Q16R and Q61K), TERT promoter mutation (-124G>A and -146G>A), RET/PTC 
rearrangement (RET/PTC1 and RET/PTC3), PAX/8PPARγ rearrangement, one year 
disease-free survival (yes/no), number of 131I therapies (<2, ≥2), cumulative dose of 131I 
therapies (<150mCi, ≥150mCi), number of additional therapies (<2, ≥2), type of additional 
therapies (<2, ≥2; these include additional 131I therapy, surgery, radiotherapy and tyrosine 
kinase inhibitors), disease-free survival after follow-up (yes/no), evidence of disease 
during follow-up (yes/no), recurrence of disease (yes/no) and mortality (yes/no). 
Frequency and percentage of yes/no variables and of genetic alterations are present in 
the tables only for yes and mutated or rearranged, respectively. 
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1.2 Antibodies 
 Antibodies for phosphorylated mTOR (p-mTOR) and phosphorylated S6 (p-S6) 
were purchased from Cell Signaling Technology®  – phospho-mTOR Ser2448 49F9 
rabbit mAb #2976 and phospho-S6 ribosomal protein Ser235/236 D57.2.2E XP® rabbit 
mAb #4858.  
 
 
METHODS 
 
1.1 Sample Preparation 
 FFPE samples were cut by a professional pathology technician using a microtome 
(Shandon™ Finesse™ 325, Thermo Scientific, MA, USA) into 3µm thick sections. The 
sections were mounted onto positively charged slides and labeled with the corresponding 
case number. Slides were placed in an incubator at 37ºC for 24 hours to dry, and at 65ºC 
for 10-15 minutes, to make sure tissue sections adhered correctly to the slides, right 
before immunohistochemistry.  
  
1.2 Hematoxylin-Eosin Staining 
The paraffin from FFPE sections was completely removed by immersion in xylene 
(Atom Scientific Ltd, United Kingdom) for 2 x 10 minutes and rehydrated in a series of 
decreasing alcohol (Aga – Álcool e Géneros Alimentares, S.A., Portugal) concentrations – 
2 x 100%, 95% and 70% – for 5 minutes in each concentration, followed by 5 minutes in 
running water, all at room temperature.  
 Samples were then stained with Mayer’s hematoxylin (DiaPath, Italy) for 4 minutes 
and rinsed in running water for 5 minutes, followed by 5 minutes in 95% alcohol (Aga – 
Álcool e Géneros Alimentares, S.A., Portugal), both at room temperature. Eosin (Eosin-Y 
Alcoholic, Richard-Allan Scientific™, Thermo Scientific, MA, USA) staining followed for 4 
minutes at room temperature. 
 The samples were dehydrated in a series of increasing alcohol (Aga – Álcool e 
Géneros Alimentares, S.A., Portugal) concentrations – 95% and 2 x 100% - for 5 minutes 
in each condition at room temperature. The subsequent step consisted of diaphonization 
with xylene (Atom Scientific Ltd, United Kingdom) for 2 x 10 minutes at room temperature.  
  Finally, the slides were mounted using a toluene-based mounting medium 
(Richard-Allan Scientific™Mounting Medium, Thermo Scientific, MA, USA). 
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1.3 Immunohistochemistry 
 Immunohistochemistry was performed using specific markers of the mTOR 
pathway. 
The paraffin from FFPE sections was completely removed by immersion in xylene 
(Atom Scientific Ltd, United Kingdom) for 2 x 10 minutes and rehydrated in a series of 
decreasing alcohol (Aga – Álcool e Géneros Alimentares, S.A., Portugal) concentrations – 
2 x 100%, 95% and 70% – for 5 minutes in each concentration, followed by 5 minutes in 
running water.  
Antigen retrieval was performed through heat-induced epitope retrieval, slides 
placed in a slide rack inside a small container, using citrate (#s/3320/60, Thermo Fisher 
Scientific Inc., UK) buffer 10mM pH6 for p-mTOR and EDTA (#4050, OmniPur® EDTA, 
Calbiochem, Merck Millipore, MA, USA) buffer 10mM pH9 for p-S6 in a microwave in 
decreasing power increments – 600W, 450W, 300W and 150W – for a total of 10 minutes. 
Slides were left to cool for 30 minutes at room temperature and then rinsed 2 x 5 minutes 
in PBS-Tween 0,02% (PBS-T) pH7.  
 Endogenous activity was blocked in three phases. First, endogenous peroxidase 
was blocked using a solution of 30% peroxidase with methanol (EMPLURA®, Merck 
Millipore, MA, USA) – 10% peroxidase and 90% methanol – incubated for 10 minutes at 
room temperature followed by a 2 x 5 minute rinse with PBS-T. Secondly, avidin and 
biotin were blocked using the Avidin/Biotin Blocking System (#TA-015-BB, Thermo 
Scientific, MA, USA), for a 10 minute incubation period at room temperature and 2 x 5 
minutes PBS-T rinse afterwards, for each of the proteins. Thirdly, for reduction of non-
specific background, the UltraVision Protein Block (#TA-125-PBQ, Thermo Scientific, MA, 
USA) was used for a 10 minute incubation period at room temperature. 
 The tissue sections were then incubated with the primary antibodies p-S6 and p-
mTOR. Antibodies were diluted with the UltraAb Diluent (#TA-125-UD, Thermo Scientific, 
MA, USA), with dilution ratios of 1:100 and 1:400 for p-mTOR and p-S6, respectively. 
Incubation was done overnight at 4ºC.  
 On the following day, the slides were rinsed for 2 x 5 minutes with PBS-T. 
Incubation with secondary antibody was performed using the Biotinylated Goat Anti-
Polyvalent solution (#TP-125-BN, Thermo Scientific, MA, USA) for 10 minutes followed by 
a 2 x 5 minute rinse with PBS-T.  
 Streptavidin/peroxidase was labeled using the Streptavidin/Peroxidase solution 
(#TS-125-HR, Thermo Scientific, MA, USA), and incubated for 10 minutes at room 
temperature and rinsed for 2 x 5 minutes PBS-T. 
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 Chromogenic detection was based on peroxidase activity using 3,3’ – 
Diaminobenzidine (DAB) (#K3468, Dako, Denmark), and incubating the samples for 2 
minutes at room temperature. 
 Samples are subsequently counterstained with Mayer’s hematoxilyn (DiaPath, 
Italy) for 4 minutes, followed by a 5 minute rinse in running water and dehydration in a 
series of increasing alcohol (Aga – Álcool e Géneros Alimentares, S.A., Portugal) 
concentrations – 95% and 2 x 100% - for 5 minutes in each condition at room 
temperature. The subsequent step consisted of diaphonization with xylene (Atom 
Scientific Ltd, United Kingdom) for 2 x 10 minutes at room temperature.  
  The last step in this technique consisted of mounting the slides using a toluene-
based mounting medium (Richard-Allan Scientific™Mounting Medium, Thermo Scientific, 
MA, USA). 
 
1.4 Classification of the Immunohistochemical staining 
 Slides were observed under an optical microscope and each case classified 
semiquantitatively by an experienced pathologist in terms of percentage of stained cells 
(0, <5%; 1, 5-25%; 2, 25-50%; 3, 50-75%; 4, >75%), intensity of staining (0, negative; 1, 
weak; 2, intermediate; 3, strong) and cellular localization of the staining (membrane and/or 
cytoplasmic) An immunohistochemical score was obtained by multiplying the percentage 
of stained cells by the intensity of the staining, with 12 being the maximum score. This 
classification system was previously used in studies of our group at Ipatimup [113]. We 
considered negative as 0, low score from 1 to 3, intermediate 4 and high from 6 to 12. 
  
1.5 Statistical Analysis 
 Statistical analysis was carried out using IBM SPSS Statistics Version 23 (IBM, 
NY, USA). The relationship between clinico-pathological characteristics and expression of 
p-S6 and p-mTOR was examined by an unpaired Student’s t test, and the results 
expressed in mean ± standard deviation. A non-parametric Mann-Whitney U-test was 
applied for sample sizes smaller than 30, and results expressed in mean rank and U-test. 
Furthermore, we obtained frequency tables for each of the variables, expressed in 
frequency and percentage. We considered statistically significant P-value < 0.05.  
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RESULTS 
 
SERIES 1 
 
1.1 Distribution of Pathological and Molecular Characteristics  
This series included a total of 90 cases of thyroid carcinoma, comprised of 73 
PTC, 13 FTC, 2 PDTC and 2 cases of PTC metastasis. Subdividing the PTC into its 
variants, there are 39 classical variants of PTC (cPTC), 23 follicular variants of PTC 
(fvPTC), 5 mixed PTCs, 3 sclerosing variants of PTC (sPTC), 1 tall cell variant of PTC 
(tcPTC), 1 oncocytic variant of PTC (oPTC) and 1 solid trabecular PTC (stPTC) – Table 2. 
The pathological data of the series lacked information in some of the cases, which were 
presented as missing information in the database. 
 
Table 2 – Diagnosis of the tumors present in Series 1 (n=90) 
Diagnosis Frequency Percentage (%) 
PTC 
cPTC 39 43.3 
fvPTC 23 25.6 
mixed PTC 5 5.6 
sPTC 3 3.3 
tcPTC 1 1.1 
oPTC 1 1.1 
stPTC 1 1.1 
FTC 13 14.4 
PDTC 2 2.2 
Metastasis PTC 2 2.2 
Total 90 100 
 
 Of the 90 cases, the mean age was 44, ranging from 11 to 82 years. The 
majority were younger than 45 years (52.2%). 75 cases (83.3%) were female, with a 
mean age of 44 (13-82) years and 14 cases (15.6%) were male, with a mean age of 41 
(11-80) years. 
 Tumors had mainly more than 2 centimeters (cm) in their biggest diameter 
(66.7%), had a single nodule at presentation (51.1%) and were encapsulated (58.9%). Of 
those that had a tumor capsule (n=53), 62.3% had invasion of the capsule. Furthermore, 
51.1% of the tumors had vascular invasion and 67.8% extended beyond the thyroid. The 
majority of tumors had no sign of lymph node metastasis (56.7%) or lymphocytic infiltrate 
(52.2%). The majority of cases were stage I (61.1%) – Table 3. 
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As far as genetic alterations go, 26.7% of the tumors were mutated for BRAF, 
12.2% for NRAS, 4.4% for TERT promoter, and 12.2% and 2.2% had rearrangements of 
RET/PTC and PAX8/PPARγ, respectively. 
 
Table 3 – Pathological and molecular characteristics of the whole series (n=90), PTC (n=73) and FTC (13) in Series 1 
Variables 
All cases 
(n=90) 
PTC 
(n=73) 
FTC 
(n=13) 
Age 
(%) 
<45 years 47 
(52.2) 
41 
(56.2) 
5 
(38.5) 
≥45 years 42 
(46.7) 
31 
(42.5) 
8 
(61.5) 
Gender 
(%) 
Female 75 
(83.3) 
61 
(83.6) 
11 
(84.6) 
Male 14 
(15.6) 
11 
(15.1) 
2 
(15.4) 
Tumor size 
(%) 
<2cm 29 
(32.2) 
28 
(38.4) 
1 
(7.7) 
≥2cm 60 
(66.7) 
44 
(60.3) 
12 
(92.3) 
Tumor capsule 
(%) 
53 
(58.9) 
38 
(52.1) 
13 
(100) 
Tumor capsule invasion 
(%) 
33 
(62.3) 
17 
(44.7) 
11 
(84.6) 
Multifocality 
(%) 
Single 46 
(51.1) 
39 
(53.4) 
5 
(38.5) 
Multiple 42 
(46.7) 
32 
(43.8) 
8 
(61.5) 
Vascular invasion 
(%) 
46 
(51.1) 
33 
(45.2) 
10 
(76.9) 
Lymph node metastasis 
(%) 
24 
(26.7) 
22 
(30.1) 
1 
(7.7) 
Extrathyroid extension 
(%) 
25 
(27.8) 
23 
(31.5) 
1 
(7.7) 
Lymphocytic infiltrate 
(%) 
40 
(44.4) 
35 
(47.9) 
4 
(30.8) 
BRAF mutation 
(%) 
24 
(26.7) 
24 
(32.9) 
0 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 
 39 
Note: the number of cases with missing information is presented in Table 1 in the Supplementary Tables 
 
Our interest for this work was mainly in PTC, so we conducted a separate analysis 
for those cases.  
There were 73 PTC in total – Table 4. Of the whole PTC cases, 83.6% were 
female and 15.1% male, and the majority of the cases were younger than 45 years 
(56.2%), with a mean of 43 (11-82) years. 
 
Table 4 – Diagnosis of the cases of papillary thyroid carcinoma (n=73) in Series 1 
Diagnosis Frequency Percentage (%) 
cPTC 39 53.4 
fvPTC 23 31.5 
mixed PTC 5 6.8 
sPTC 3 4.1 
tcPTC 1 1.4 
oPTC 1 1.4 
stPTC 1 1.4 
Total 73 100 
 
 The same variables mentioned above were also analyzed for this group (n=73). 
For the majority of the variables, the same tendency observed when analyzing all the 
cases was found – i.e. tumors ≥2cm (60.3%), tumor encapsulation (52.1%), invasion of 
NRAS mutation 
(%) 
11 
(12.2) 
7 
(9.6) 
3 
(23.1) 
TERT promoter mutation 
(%) 
4 
(4.4) 
2 
(2.7) 
1 
(7.7) 
RET/PTC rearrangement 
(%) 
11 
(12.2) 
10 
(13.7) 
1 
(7.7) 
PAX8/PPARγ  rearrangement 
(%) 
2 
(2.2) 
1 
(1.4) 
1 
(7.7) 
Staging 
(%) 
I 55 
(61.1) 
48 
(65.8) 
6 
(46.2) 
II 9 
(10.0) 
4 
(5.5) 
4 
(30.8) 
III 14 
(15.6) 
11 
(15.1) 
2 
(15.4) 
IVa 6 
(6.7) 
5 
(6.8) 
1 
(7.7) 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 40 
tumor capsule (44.7% of the tumors with capsule), single nodule at presentation (53.4%), 
no lymph node metastasis (54.8%), no lymphocytic infiltrate (50.7%) and stage I disease 
(65.8%). On the other hand, the majority of PTC do not present vascular invasion (54.8%) 
nor extrathyroid extension (63.0%) – Table 3.  
 
 We also did a comparative analysis between cPTC and fvPTC to see the 
distribution of the clinico-pathological characteristics within those variants – Table 5.  
 
 
Table 5 – Pathological and molecular characteristics of cPTC (n=39) and fvPTC (n=23) in Series 1 
Variables cPTC (n=39) fvPTC (n=23) 
Age 
(%) 
<45 years 
22 
(56.4) 
11 
(47.8) 
≥45 years 
17 
(43.6) 
11 
(47.8) 
Gender 
(%) 
Female 
35 
(89.7) 
18 
(78.3) 
Male 
4 
(10.3) 
4 
(17.4) 
Tumor size 
(%) 
<2cm 
15 
(38.5) 
8 
(34.8) 
≥2cm 
23 
(59.0) 
15 
(65.2) 
Tumor capsule 
(%) 
17 
(43.6) 
13 
(56.5) 
Tumor capsule invasion 
(%) 
11 
(64.7) 
3 
(23.1) 
Multifocality 
(%) 
Single 
21 
(53.8) 
11 
(47.8) 
Multiple 
16 
(41) 
12 
(52.2) 
Vascular invasion 
(%) 
23 
(59) 
4 
(17.4) 
Lymph node metastasis 
(%) 
14 
(35.9) 
4 
(17.4) 
Extrathyroid extension 
(%) 
12 
(30.8) 
4 
(17.4) 
Lymphocytic infiltrate 
(%) 
25 
(64.1) 
6 
(26.1) 
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Note: the number of cases with missing information is presented in Table 2 in the Supplementary Tables 
 
cPTC turned out to be the variant with the most features associated with 
aggressive behavior – 53.8% of tumors without capsule, and of those with tumor capsule, 
64.7% had tumor capsule invasion, 59.0% of tumors with vascular invasion and 64.1% 
with lymphocytic infiltrate. This variant also presented with more tumors with a single 
nodule (53.8%) and in younger patients (56.4%).  
 fvPTC presented tumors with a more indolent behavior – 56.5% with tumor 
capsule, and of those, only 23.1% with invasion of the capsule, 82.6% of tumors without 
vascular invasion and 69.6% without lymphocytic infiltrate. Tumors were equally 
distributed between ages (47.8% for patients <45 years and ≥45 years), and were 
multifocal at presentation (52.2%).  
 
1.2 Association of p-S6 and p-mTOR with Pathological and Molecular 
Characteristics in PTC   
 
p-S6 expression in PTC 
The distribution of p-S6 scores is presented in Table 6.  
 
BRAF mutation 
(%) 
19 
(48.7) 
3 
(13) 
NRAS mutation 
(%) 
1 
(2.6) 
3 
(13) 
TERT promoter mutation 
(%) 
1 
(2.6) 
1 
(4.3) 
RET/PTC rearrangement 
(%) 
7 
(17.9) 
2 
(8.7) 
PAX8/PPARγ  rearrangement 
(%) 
0 
1 
(4.3) 
Staging 
(%) 
I 
27 
(69.2) 
14 
(60.9) 
II 
2 
(5.1) 
1 
(4.3) 
III 
6 
(15.4) 
3 
(13) 
IVa 
3 
(7.7) 
2 
(8.7) 
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Table 6 – Distribution of p-S6 score in PTC (n=73) in Series 1 
Score Frequency Percentage (%) 
0 17 23.3 
1 9 12.3 
2 7 9.6 
3 5 6.8 
4 10 13.7 
6 9 12.3 
8 4 5.5 
9 6 8.2 
12 6 8.2 
Total 73 100 
Note: the distribution of the p-S6 scores in each variant of PTC is presented in Table 3 in the Supplementary Tables 
 
There is a considerable number of negative cases (23.3%) or with a low (from 0-3) 
score (42.1%). Only 13.7% of cases had an intermediate score of 4, and about one third 
(34.2%) of the cases scored 6 or above.  
 
 In Table 7 are presented the statistically significant results obtained in the 
comparison of pathological and molecular characteristics. We included BRAF and NRAS 
mutations, which had a borderline statistically significant P-value. 
   
Table 7 – Associations between p-S6 score in PTC and pathological and molecular characteristics (n=73) in Series 1 
Variables Frequency P-value Mean Standard deviation 
Tumor capsule invasion 
Yes 20 
0.011 
2.65 3.233 
No 17 5.71 3.378 
Extrathyroid extension 
Yes 23 
0.018 
2.57 2.873 
No 46 4.61 4.025 
Lymphocytic infiltrate 
Yes 35 
0.001 
2.43 2.779 
No 37 5.30 4.027 
BRAF mutation 
WT 49 
0.071 
4.49 3.964 
Mutated 24 2.92 3.134 
NRAS mutation 
WT 66 
0.087 
3.73 3.813 
Mutated 7 6.29 2.360 
 
 
 There were statistically significant associations between p-S6 score and tumor 
capsule invasion, extrathyroid extension and lymphocytic infiltrate. Cases without tumor 
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capsule invasion (P-value=0.001), without extrathyroid extension (P-value=0.018) and 
without lymphocytic infiltrate (P-value=0.001) had a greater p-S6 score. 
A tendency was observed between p-S6 score and BRAF and NRAS mutations. 
Wild type (WT) BRAF (P-value=0.071) and NRAS mutated (P-value=0.087) cases had 
higher p-S6 score. 
 
p-mTOR expression in PTC 
 For p-mTOR, we found that the majority of cases scored above 6 (67.1%), 
whereas only 21.9% scored negative or low – Table 8.  
 
Table 8 – Distribution of p-mTOR score in PTC (n=73) 
Score Frequency Percentage (%) 
0 5 6.8 
1 3 4.1 
2 4 5.5 
3 4 5.5 
4 8 11.0 
6 13 17.8 
9 11 15.1 
12 25 34.2 
Total 73 100 
Note: the distribution of the p-mTOR scores in each variant of PTC is presented in Table 4 in the Supplementary Tables 
 
 
 We only observed one statistical significant association. Cases with extrathyroid 
extension had higher p-mTOR score (P-value=0.027) – Table 9. 
 
Table 9 – Associations between p-mTOR score and pathological characteristics in PTC (n=73) in Series 1 
 
 
 
cPTC and fvPTC 
We also did the same analysis considering cPTC and fvPTC separately. For both 
markers, we had 39 cPTC cases and 23 fvPTC cases analyzed. Distribution of p-S6 
scores for both variants is presented in Table 10.  
Variables Frequency P-value Mean Standard deviation 
Extrathyroid extension 
Yes 23 
0.027 
8.87 3.548 
No 46 6.52 4.299 
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Table 10 – Distribution of p-S6 score in cPTC (n=39) and fvPTC (n=23) in Series 1 
 cPTC (n=39) fvPTC (n=23) 
Score Frequency Percentage (%) Frequency Percentage (%) 
0 11 28.2 3 13 
1 4 10.3 4 17.4 
2 5 12.8 0 0 
3 4 10.3 1 4.3 
4 5 12.8 3 13 
6 3 7.7 5 21.7 
8 2 5.1 2 8.7 
9 2 5.1 2 8.7 
12 3 7.7 3 13 
Total 39 100 23 100 
 
 In cPTC (n=39), the majority of cases stained with p-S6 scored negative or low 
(61.6%) and 25.6% had a high score. On the other hand, fvPTC (n=23) had high scores in 
52.1% of cases and negative or low scores in 34.7%.   
 
  
Table 11 – Distribution of p-mTOR score in cPTC (n=39) and fvPTC (n=23) in Series 1 
 cPTC (n=39) fvPTC (n=23) 
Score Frequency Percentage (%) Frequency Percentage (%) 
0 2 5.1 3 13 
1 1 2.6 2 8.7 
2 1 2.6 2 8.7 
3 2 5.1 2 8.7 
4 5 12.8 2 8.7 
6 10 25.6 1 4.3 
9 6 15.4 3 13 
12 12 30.8 8 34.8 
Total 39 100 23 100 
 
For p-mTOR, 15.4% cPTC cases had a negative or low score and 71.8% had a 
high score. When looking at fvPTC, a little more than one third (39.1%) of cases had a 
negative or low score and about half (52.1%) of the cases had a high score – Table 11. 
 
 
 No significant differences in p-S6 expression were found for cPTC. p-mTOR score 
showed a significant association with two variables – multifocality and extrathyroid 
extension – Table 12. 
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Table 12 – Associations between p-mTOR score and pathological characteristics in cPTC (n=39) in Series 1 
Variables Frequency P-value Mean Standard deviation 
Multifocality 
Single 21 
0.018 
8.87 3.651 
Multiple 16 5.63 3.739 
Extrathyroid extension 
Yes 12 
0.028 
9.42 3.175 
No 26 6.46 3.901 
 
Cases with a single nodule at presentation (P-value=0.018) and those with 
extrathyroid extension (P-value=0.028) had a higher p-mTOR score.  
 
For fvPTC (n=23), there were no significant differences in p-mTOR expression, but 
p-S6 score associated with lymphocytic infiltrate – Table 13.  
 
Table 13 – Associations between p-S6 score and pathological characteristics in fvPTC (n=23) 
Variables Frequency P-value Mean Rank U-test 
Lymphocytic infiltrate 
Yes 6 
0.027 
6.50 
18.000 
No 16 13.38 
 
Cases with no lymphocytic infiltrate had higher p-S6 score (P-value=0.027). 
 
1.3 Cellular localization of staining 
 Within the tumors, we observed that both p-S6 and p-mTOR had a more intense 
staining in the periphery, a result that was more consistent with p-mTOR.  We also 
observed that that staining was located mainly on the membrane and cytoplasm for p-
mTOR and cytoplasmic only for p-S6. The staining was highly heterogeneous within the 
tumors (Supplementary Figures 1, 3-B and 4-B).  
 
 
SERIES 2 
 
2.1 Distribution of Clinico-pathological and Molecular Characteristics  
This series included a total of 127 cases of thyroid carcinoma, comprised of 114 
PTC, 6 FTC and 7 PDTC. Subdividing the PTC into its variants, there are 77 cPTC, 28 
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fvPTC, 4 sPTC, 1 oPTC, 1 tcPTC and 3 Warthin-like variant of PTC (wPTC) – Table 14. 
The clinicopathological data of Series 2 lacked information in some of the cases, which 
were presented as missing information in the database.  
 
Table 14 – Distribution of the cases present in Series 2 (n=127) 
Diagnosis Frequency Percentage (%) 
PTC 
cPTC 77 60.6 
fvPTC 28 22 
sPTC 4 3.1 
oPTC 1 0.8 
tcPTC 1 0.8 
wPTC 3 2.4 
FTC 6 4.7 
PDTC 7 5.5 
Total 127 100 
 
Of the 127 cases, the mean age was 47, ranging from 13 to 79 years, and the 
majority of patients being 45 years or older (51.2%). The majority of cases (77.2%) were 
female, with a mean age of 45 (13-74) years and 29 cases (22.8%) were male, with a 
mean age of 50 (17-79) years.  
Tumors had mainly more than 2 cm in their biggest diameter (58.3%), had a single 
nodule at presentation (55.9%), had infiltrative margins (61.4%) and were encapsulated 
(59.1%). Of those that had a tumor capsule (n=75), 92% had invasion of the capsule. 
Furthermore, 44.1% had lymph node metastases and 19.7% had distant metastases. In 
terms of peritumoral invasiveness, 28.3%, 57.7% and 40.2% had vascular invasion, 
thyroid capsule invasion and extrathyroid extension, respectively. All of this characteristics 
contributed to place the majority of tumors at stage I (54.3%). 
 
Table 15 – Clinico-pathological and molecular characteristics of the whole series (n=127), PTC (n=114) and FTC (n=6) in 
Series 2 
Variables 
All cases 
(n=127) 
PTC 
(n=114) 
FTC 
(n=6) 
Age 
(%) 
<45 years 
61 
(48) 
58 
(50.9) 
2 
(33.3) 
≥45 years 
65 
(51.2) 
55 
(48.2) 
4 
(66.7) 
Gender 
(%) 
Female 
98 
(77.2) 
90 
(78.9) 
4 
(66.7) 
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Male 
29 
(22.8) 
24 
(21.1) 
2 
(33.3) 
Lymph node metastases 
(%) 
56 
(44.1) 
54 
(47.4) 
0 
Distant metastases 
(%) 
25 
(19.7) 
15 
(13.2) 
4 
(66.7) 
Tumor size 
(%) 
<2cm 
43 
(33.9) 
43 
(37.7) 
- 
≥2cm 
74 
(58.3) 
65 
(57) 
4 
(66.7) 
Tumor capsule 
(%) 
75 
(59.1) 
65 
(57) 
5 
(83.3) 
Tumor capsule invasion 
(%) 
70 
(93.3) 
60 
(92.3) 
5 
(100) 
Vascular invasion 
(%) 
36 
(28.3) 
28 
(24.6) 
3 
(50) 
Tumor margins 
(%) 
Well defined 
 
42 
(33.1) 
34 
(29.8) 
4 
(66.7) 
Infiltrative 
 
78 
(61.4) 
76 
(66.7) 
1 
(16.7) 
Thyroid capsule invasion 
(%) 
73 
(57.5) 
70 
(61.4) 
3 
(50) 
Extrathyroid extension 
(%) 
51 
(40.2) 
50 
(43.9) 
- 
Multifocality 
(%) 
Single 
71 
(55.9) 
64 
(56.1) 
3 
(50) 
Multiple 
47 
(37) 
44 
(38.6) 
2 
(33.3) 
Lymphocytic infiltrate 
(%) 
77 
(60.6) 
71 
(62.3) 
3 
(50) 
Staging 
(%) 
I 
69 
(54.3) 
66 
(57.9) 
1 
(16.7) 
II 
9 
(7.1) 
6 
(5.3) 
2 
(33.3) 
III 
28 
(22) 
26 
(22.8) 
1 
(16.7) 
IVa 
6 
(4.7) 
6 
(5.3) 
- 
IVc 6 4 1 
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Note: the number of cases with missing information is presented in Table 5 in the Supplementary Tables.  
 
With reference to genetic alterations, 46.5% were mutated for BRAF, 2.4% for 
NRAS and 11% for TERT promoter.  
Regarding the therapeutic aspect, the majority of cases had less than two 131I 
therapies (52%) and a cumulative dose of 131I lower than 150 mCi (50.4%). One third of 
(4.7) (3.5) (16.7) 
BRAF mutation 
(%) 
59 
(46.5) 
56 
(49.1) 
- 
NRAS mutation 
(%) 
3 
(2.4) 
3 
(2.6) 
 
- 
TERT promoter mutation 
(%) 
14 
(11) 
8 
(7) 
4 
(66.7) 
One year disease-free survival 
(%) 
70 
(55.1) 
64 
(56.1) 
1 
(16.7) 
Number of 131I therapies 
(%) 
<2 
66 
(52) 
61 
(53.5) 
1 
(16.7) 
≥2 
57 
(44.9) 
49 
(43) 
5 
(83.3) 
Cumulative dose 
(%) 
<150mCi 
64 
(50.4) 
60 
(52.6) 
0 
≥150mCi 
58 
(45.7) 
49 
(43) 
6 
(100) 
Number of additional 
therapies 
(%) 
<2 
16 
(12.6) 
15 
(13.2) 
1 
(16.7) 
≥2 
47 
(37) 
39 
(34.2) 
5 
(83.3) 
Type of additional 
therapies 
(%) 
1 type 
34 
(53.9) 
32 
(59.3) 
2 
(33.3) 
More than 1 type 
29 
(46.1) 
22 
(40.7) 
4 
(66.7) 
Disease-free survival after follow-up 
(%) 
74 
(58.3) 
70 
(61.4) 
1 
(16.7) 
Evidence of disease during follow-up 
(%) 
41 
(77.4) 
35 
(76.1) 
4 
(66.7) 
Recurrence 
(%) 
66 
(52) 
56 
(49.1) 
6 
(100) 
Mortality 
(%) 
9 
(7.1) 
5 
(4.4) 
1 
(16.7) 
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the cases had two or more additional therapies (37%), and of those that needed additional 
therapies, 53.9% had undergone one type of therapy. Concerning clinical outcome, 55.1% 
of cases were free of disease after 1 year and 58.3% free of disease after follow-up, which 
had a mean of 101.27 (3-467) months, but the majority had recurrence of disease (52%). 
Of those that had persistence of disease after one year, we combined them with the 
results from the variable Disease free after follow-up, and observed that 77.4% of those 
cases had evidence of disease during follow-up. The mortality rate observed was 7.1% – 
Table 15.   
 
In the separate analysis for PTC, there were 114 cases in total – Table 16.  
 
Table 16 – Distribution of PTC histotypes (n=114) 
Diagnosis Frequency Percentage (%) 
PTC 
cPTC 77 67.5 
fvPTC 28 24.6 
sPTC 4 3.5 
oPTC 1 0.9 
tcPTC 1 0.9 
wPTC 3 2.6 
Total 114 100 
 
The mean age in PTC was 46, ranging from 13 to 79 years, and the majority being 
younger than 45 years (50.9%). Ninety cases (78.9%) were female, with a mean age of 45 
(13-74) years and 24 cases (21.1%) were male, with a mean age of 50 (17-79) years. 
 
We observed in PTC (n=114) the same tendencies as we did for the whole series. 
Tumors were ≥2cm (57%), presented as a single nodule (56.1%), had infiltrative margins 
(66.7%), lymphocytic infiltrate (62.3%), presence of tumor capsule (57%), with 90.8% of 
those invading the capsule, and invasion of thyroid capsule (61.4%).  
In comparison with the whole series, there were less tumors with vascular invasion 
(24.6%), extrathyroid extension (43.9%), lymph node metastases (47.4%) and distant 
metastases (13.2%). For the most part, tumors were also staged at stage I (57.9%).  
Mutation of BRAF was the most common genetic alteration (49.1%), whereas 
NRAS mutation and TERT promoter mutation were present in only a small part of tumors 
(2.6% and 7%, respectively).  
In most cases, it was shown that they were free of disease after 1 year (56.1%) 
and at the end of follow-up as well (61.4%), but 76.1% had evidence of disease during 
follow-up and about half had disease recurrence (49.1%). Follow-up mean was 93.7 (3-
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325) months. Mortality rate was at 4.4%. With regards to therapeutic data, the great part 
of these cases underwent less than 2 131I therapies (53.5%) with a cumulative dose of less 
than 150 mCi (52.6%). About a third (34.2%) had to receive two or more additional 
therapies, with 59.3% of those requiring only 1 type of therapy – Table 15. 
 
We performed a comparative analysis between cPTC and fvPTC in order to see 
the distribution of the clinico-pathological and molecular characteristics within those 
variants – Table 17.  
 
Table 17 – Clinico-pathological and molecular characteristics in cPTC (n=77) and fvPTC (n=28) in Series 2 
Variables 
cPTC 
(n=77) 
fvPTC 
(n=28) 
Age 
(%) 
<45 years 
41 
(53.2) 
14 
(50) 
≥45 years 
36 
(46.8) 
14 
(50) 
Gender 
(%) 
Female 
60 
(77.9) 
24 
(85.7) 
Male 
17 
(22.1) 
4 
(14.3) 
Lymph node metastases 
(%) 
41 
(53.2) 
8 
(28.6) 
Distant metastases 
(%) 
9 
(11.7) 
4 
(14.3) 
Tumor size 
(%) 
<2cm 
27 
(35.1) 
12 
(42.9) 
≥2cm 
44 
(57.1) 
16 
(57.1) 
Tumor capsule 
(%) 
37 
(48.1) 
23 
(82.1) 
Tumor capsule invasion 
(%) 
20 
(86.9) 
35 
(94.6) 
Vascular invasion 
(%) 
22 
(28.6) 
5 
(17.9) 
Tumor margins 
(%) 
Well defined 
 
16 
(20.8) 
15 
(53.6) 
Infiltrative 
 
57 
(74) 
13 
(46.4) 
Thyroid capsule invasion 53 11 
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(%) (68.8) (39.3) 
Extrathyroid extension 
(%) 
40 
(51.9) 
7 
(25) 
Multifocality 
(%) 
Single 
36 
(46.8) 
22 
(78.6) 
Multiple 
36 
(46.8) 
6 
(21.4) 
Lymphocytic infiltrate 
(%) 
49 
(63.6) 
19 
(67.9) 
Staging 
(%) 
I 
47 
(61) 
15 
(53.6) 
II 
3 
(3.9) 
3 
(10.7) 
III 
20 
(26) 
4 
(14.3) 
IVa 
3 
(3.9) 
2 
(7.1) 
IVc - 
3 
(10.7) 
BRAF mutation 
(%) 
43 
(55.8) 
8 
(28.6) 
NRAS mutation 
(%) 
8 
(10.4) 
2 
(7.1) 
TERT promoter mutation 
(%) 
5 
(6.5) 
3 
(10.7) 
1 year disease-free survival 
(%) 
42 
(54.5) 
19 
(67.9) 
Number of 131I therapies 
(%) 
<2 
39 
(50.6) 
18 
(64.3) 
≥2 
36 
(46.8) 
10 
(35.7) 
Cumulative dose 
(%) 
<150mCi 
38 
(49.4) 
18 
(64.3) 
≥150mCi 
36 
(46.8) 
10 
(35.7) 
Number of additional therapies 
(%) 
<2 
11 
(14.3) 
3 
(10.7) 
≥2 
30 
(39) 
7 
(25) 
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Note: the number of cases with missing information is presented in Table 6 in the Supplementary Tables.  
 
cPTC turned out to be associated with more aggressive features – presence of 
lymph node metastases (53.2%), infiltrative tumor margins (74%), invasion of thyroid 
capsule (68.8%) and extrathyroid extension (51.9%). Single and multifocal nodules had 
the same distribution (46.8%) and the majority of patients were younger than 45 years 
(53.2%). Follow-up mean was 105.23 (9-467) months. 
On the other hand, fvPTC (n=28) were associated with less aggressive features – 
71.4% of tumors had no signs of lymph node metastases, 53.6% of tumors had well 
defined margins, 57.1% had no thyroid capsule invasion, 75% did not extend beyond the 
thyroid and 78.6% of tumors presented with a single nodule. Age was equally distributed 
between groups (50%). Follow-up median was 71 (3.325) months.  
 
2.2 Association of p-S6 and p-mTOR with Clinico-pathological and 
Molecular Characteristics 
We had difficulties classifying some cases, mainly for p-S6, because there was no 
positive staining of internal tissue control, which deemed these samples unviable for the 
study, and therefore excluded from the analysis. The best hypothesis to support this was 
poor fixation of tissue. For this reason, we had to exclude from the statistical analysis 38 
cases of p-S6 and 7 cases of p-mTOR (Supplementary Data Figure 2).  
 
p-S6 in PTC 
 The distribution of p-S6 score in PTC (n=76) is presented in Table 18.  
 
Type of additional therapies 
(%) 
1 type 
23 
(56.1) 
7 
(70) 
More than 1 type 
18 
(43.9) 
3 
(30) 
Disease-free survival after follow-up 
(%) 
44 
(57.1) 
20 
(71.4) 
Evidence of disease during follow-up 
(%) 
26 
(81.5) 
7 
(77.8) 
Recurrence 
(%) 
41 
(53.2) 
10 
(35.7) 
Mortality 
(%) 
2 
(2.6) 
2 
(7.1) 
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Table 18 – Distribution of p-S6 score in PTC (n=76) in Series 2 
Score Frequency Percentage (%) 
0 34 44.7 
1 12 15.8 
2 11 14.5 
3 7 9.2 
4 3 3.9 
6 5 6.6 
9 2 2.6 
12 2 2.6 
Total 76 100 
Note: the distribution of p-S6 scores in each variant of PTC is presented in Table 7 of Supplementary Tables 
 
 We had 38 cases excluded for this analysis, thus totaling 76 cases, and not the 
total 114. The majority of cases (84.2%) scored negative or low and 11.8% scored high.  
 
 Table 19 presents the statistically significant results. We also included tumor 
margins and thyroid capsule invasion, which had a borderline statistically significant P-
value. 
 
Table 19 – Associations between p-S6 score and pathological characteristics in PTC (n=76) in Series 2 
Variables Frequency P-value Mean Standard deviation 
Tumor capsule 
No 35 
0.001 
0.74 1.379 
Yes 38 2.87 3.223 
Vascular invasion 
No 53 
0.045 
1.38 2.132 
Yes 19 3.26 3.664 
Tumor margins 
Infiltrative 53 
0.053 
1.47 2.636 
Well defined 20 2.85 2.739 
Thyroid capsule 
invasion 
No 26 
0.069 
2.65 3.224 
Yes 45 1.42 2.360 
  
Cases with invasion of tumor capsule (P-value=0.001) and vascular invasion (P-
value=0.045) were found to have higher scores of p-S6. We also saw a tendency between 
higher scores of p-S6 and absence thyroid capsule invasion (P-value=0.069) and well-
defined tumor margins (P-value=0.053) – Table 19. 
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p-mTOR in PTC 
 We analyzed 107 cases of PTC stained for p-mTOR, and not the 114, due to 
exclusion of 7 cases. 
 
Table 20 – Distribution of p-mTOR score in PTC (n=107) in Series 2 
Score Frequency Percentage (%) 
0 33 30.8 
1 7 6.5 
2 15 14 
3 8 7.5 
4 9 8.4 
6 9 8.4 
8 3 2.8 
9 11 10.3 
12 12 11.2 
Total 107 100 
Note: the distribution of the p-mTOR scores in each variant is presented in Table 8 of Supplementary Tables 
 
 We had 58.8% of cases with a negative or low score and 32.7% with a high score 
– Table 20. 
 
Table 21 presents the statistically significant results. We also included 
multifocality, one year disease-free survival and cumulative dose, which had a borderline 
statistically significant P-value. 
 
Table 21 – Associations between p-mTOR score and clinico-pathological characteristics in PTC (n=107) in Series 2 
Variables Frequency P-value Mean Standard deviation 
Distant metastases 
No 92 
0.049 
3.61 4.087 
Yes 14 5.93 3.912 
Tumor capsule 
No 43 
0.024 
5.00 4.342 
Yes 61 3.16 3.782 
Multifocality 
Single 61 
0.066 
3.30 3.909 
Multiple 41 4.83 4.347 
One year disease-free 
survival 
No 42 
0.053 
4.95 4.742 
Yes 61 3.26 3.521 
Cumulative dose 
<150 58 
0.090 
3.45 3.752 
>=150 44 4.89 4.489 
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 Higher p-mTOR scores were found in cases presenting distant metastases (P-
value=0.049) and in those without a tumor capsule (P-value=0.024). The presence of 
multiple nodules showed a tendency to be associated with higher p-mTOR score (P-
value=0.066), as well as persistence of disease after one year (P-value=0.053) and higher 
doses of 131I (P-value=0.090). 
 
cPTC and fvPTC 
 For p-S6, we analyzed only 51 cPTC cases, instead of 77, and 18 fvPTC cases, 
instead of 28, because of the cases that were excluded.  
 
Table 22 – Distribution of p-S6 scores in cPTC (n=51) and fvPTC (n=18) in Series 2 
 cPTC (n=51) fvPTC (n=18) 
Score Frequency Percentage (%) Frequency Percentage (%) 
0 25 49 7 38.9 
1 8 15.7 2 11.1 
2 7 13.7 4 22.2 
3 3 5.9 3 16.6 
4 2 3.9 0 0 
6 3 5.9 1 5.6 
9 1 2 1 5.6 
12 2 3.9 0 0 
Total 51 100 18 100 
 
 The majority (84.3%) of cPTC (n=51) had a negative or low p-S6 score and 11.8% 
had a high score. In fvPTC (n=18), the vast majority (88.8%) had a negative or low p-S6 
score and only 11.2% presented a high score – Table 22. 
 
 For p-mTOR, we only analyzed 73 cPTC, instead of 77, and 25 fvPTC, instead of 
28, because of the cases excluded.  
 
Table 23 – Distribution of p-mTOR score in cPTC (n=73) and fvPTC (n=25) in Series 2 
 cPTC (n=73) fvPTC (n=25) 
Score Frequency Percentage (%) Frequency Percentage (%) 
0 23 31.5 8 32 
1 7 9.6 0 0 
2 11 15.1 3 12 
3 3 4.1 3 12 
4 6 8.2 3 12 
6 7 9.6 2 8 
8 1 1.4 1 4 
9 7 9.6 3 12 
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12 8 10.9 2 8 
Total 73 100 25 100 
 
 Approximately two thirds of cPTC (60.3%) and fvPTC (68%) had a negative or low 
p-mTOR score and 31.5% of cPTC and 32% of fvPTC had a high p-mTOR score – Table 
23. 
 
We only found a significant association between high p-S6 score and presence of 
tumor capsule (P-value=0.017) in cPTC. 
 
Table 24 – Associations between p-S6 and pathological characteristics in cPTC (n=51) in Series 2 
Variables Frequency P-value Mean Standard deviation 
Tumor capsule 
No 27 
0.017 
0.81 1.520 
Yes 21 3.05 3.761 
 
 
On the other hand, in fvPTC, cases with higher p-S6 score were significantly 
associated with presence of distant metastases (P-value=0.013) and vascular invasion (P-
value=0.005). Furthermore, cases with higher p-S6 scores show more frequently well-
defined tumor margins (P-value=0.083) and single nodules at presentation (P-
value=0.061) – Table 25. 
 
Table 25 – Associations between p-S6 and pathological characteristics in fvPTC (n=18) in Series 2 
Variables Frequency P-value Mean Rank U 
Distant metastases 
No 16 
0.013 
8.50 
0.000 
Yes 2 17.50 
Vascular invasion 
No 15 
0.005 
8.07 
1.000 
Yes 3 16.67 
Tumor margins 
Well-defined 10 
0.083 
12.00 
20.000 
Infiltrative 8 7.59 
Multifocality 
Single 22 
0.061 
10.75 
10.500 
Multiple 6 5.13 
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Regarding p-mTOR in cPTC, there were statistically significant associations with 
presence of distant metastases (P-value=0.025) and persistence of disease after follow-
up (P-value=0.048). We also obtained a borderline significance with multifocal tumors (P-
value=0.068), absence of TERT promoter mutation (P-value=0.095) and persistence of 
disease after one year (P-value=0.099) – Table 26. 
 
Table 26 – Associations between p-mTOR and clinico-pathological and molecular characteristics in cPTC (n=73) in Series 2 
Variables Frequency P-value Mean Standard deviation 
Distant metastases 
No 64 
0.025 
3.31 4.011 
Yes 9 6.56 3.644 
Multifocality 
Single 36 
0.068 
2.83 3.768 
Multiple 33 4.64 4.314 
TERT promoter 
mutation 
WT 53 
0.095 
4.04 4.206 
Mutated 5 2.20 1.789 
One year disease free 
survival 
No 28 
0.099 
4.86 4.882 
Yes 42 3.02 3.339 
Disease free survival 
after follow-up 
No 28 
0.048 
5.11 4.841 
Yes 43 2.98 3.327 
  
 
In fvPTC, we only found a significant association between p-mTOR score and 
absence of tumor capsule (P-value=0.035) – Table 27. 
 
Table 27 - Associations between p-mTOR score and pathological data in fvPTC (n=25) in Series 2 
Variables Frequency P-value Mean Rank U 
Tumor capsule 
No 5 
0.035 
19.10 
19.500 
Yes 20 11.48 
 
2.3 Cellular localization of staining 
 In this series, we observed p-S6 and p-mTOR with intense peripheral staining, 
which was more consistent with p-mTOR. It was preferentially located on the membrane 
and cytoplasm for p-mTOR and cytoplasmic only for p-S6. Staining was highly 
heterogeneous within the tumors (Supplementary Figures 1, 3-A and 4-A). 
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DISCUSSION 
 
mTOR PATHWAY ACTIVATION 
 
mTOR is a central regulator of several cellular processes, such as cell growth, 
proliferation and survival, and it is also involved in regulating cell migration. 
Understandably, this pathway is overactivated in several cancers, including thyroid 
cancer, and has been linked to its pathogenesis. PTC are usually indolent, have a good 
prognosis and ablative treatment is efficient. Unfortunately, a subset of cases will develop 
recurrence and metastases [114].  
The main goal of this work was to evaluate the activation of the mTOR pathway in 
PTC, and we accomplished this by confirming its overactivation in such cases. 
Furthermore, we have found p-mTOR to be associated with aggressive behavior and 
poorer outcomes. p-mTOR expression was significantly higher in PTC with extrathyroid 
extension and distant metastases; there was also a tendency to higher expression in 
those cases that required higher doses of 131I. Considering cPTC only, we observed a 
significant association with persistence of disease after follow-up.  
Additionally, p-mTOR was preferentially localized in the periphery of tumors, as 
well as in their invasive front, and the majority of cases had a membrane staining. Similar 
findings were also reported in renal cell carcinoma [115].  
The consistent results with p-mTOR, even taking into consideration the differences 
between series, strongly suggests that p-mTOR is highly expressed in aggressive PTC, 
and thus would be useful to evaluate behavior in these tumors. Additionally, unpublished 
data from our group reveals a significant negative correlation between p-mTOR and NIS, 
which is in accordance with what is reported on papillary thyroid cancer lineages [111]. 
Since patients with low NIS expression do not respond to ablative 131I therapy [9], once 
more, p-mTOR seems to be associated with poor prognosis.  
 Regarding p-S6, the results were not consistent between series. In Series 1, we 
found expression of p-S6 to be associated with factors of good prognosis (absence of 
invasion of tumor capsule, absence of extrathyroid extension and absence of lymphocytic 
infiltrate) and in Series 2 to be associated with vascular invasion. Interestingly, we found a 
borderline significance between high p-S6 expression and wild-type BRAF and NRAS 
mutation in PTC in Series 1. We feel that p-S6 is not a robust marker to evaluate the 
outcome in PTC. 
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Activation of the mTOR pathway has been reported in a variety of cancers. These 
studies evaluated expression of p-S6, p-mTOR and other effectors of the pathway and 
found significant associations with aggressive behavior and poorer outcomes. Activation 
of mTOR pathway via overexpression of p-mTOR was found to be associated in 
glioblastoma [116] and melanoma [117] with poor prognosis, in pancreatic 
neuroendrocrine tumors with aggressive characteristics [118] , in extrahepatic 
cholangiocarcinoma [119] and in head and neck small cell carcinoma [120]. On the 
contrary, overexpression of p-mTOR was found in luminal breast cancer [121] and small 
cell lung carcinoma [122] with good prognosis. Some authors have also found the mTOR 
pathway to be activated via overexpression of p-S6 in lung adenocarcinoma [123] and 
renal cell carcinoma [124]. 
In thyroid cancer, a few studies on mTOR pathway also demonstrated its 
activation. Faustino et al. reported p-mTOR expression in PTC, and its expression was 
associated with BRAF mutation [113]. Ahmed et al. [125] also found activation of mTOR 
pathway in PTC, although they did not find any associations with aggressive features. In 
FTC, Kirschner et al. showed activation of the mTOR pathway as well [126]. Moreover, 
overexpression of p-S6 leading to activation of the mTOR pathway was reported in 
medullary thyroid carcinoma associated with lymph node metastases [127] and RAS 
mutation [128]. With different markers, Kouvaraki et al. [129] observed activation of the 
pathway via overactivation of phosphorylated 4E-PB1 in 8 cases with aggressive histology 
as compared to cPTC.  
 
In order to better understand our results, we analyzed the correlation between p-
mTOR and p-S6 expression, and did not find any correlation (Supplementary Tables 6 
and 7). However, a previous study in our group by Populo et al. [117] showed a positive 
correlation between p-S6 and p-mTOR in melanoma cases. This was also reported in 
glioblastoma [130]. Taking this into account and the associations we found with p-mTOR 
and its localization in the tumors, we hypothesized that activation of the mTOR pathway 
was occurring through activation of mTORC2. 
Through the canonical way, mTOR activation goes through mTORC1, and in this 
case it is expected a positive correlation between expression of p-mTOR and p-S6, given 
that there are no other activators of p-S6 besides mTORC1. If the expression of p-mTOR 
does not correlate in any way with p-S6, which is what we observed, one can hypothesize 
that activation of mTOR in PTC is occurring mainly via mTORC2 (to be noted, our 
antibody recognized p-mTOR on Ser2448, which is present on both mTORC1 and 
mTORC2, whereas phosphorylation on Ser2481 is exclusive for mTORC2 [131]).  
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One of the roles of mTORC2 is the phosphorylation of Akt on Ser473, which takes 
place in the cytoplasmic membrane. Curiously, we observed p-mTOR membrane staining 
in the majority of our cases. Besides that, mTORC2 also controls cytoskeletal remodeling 
and cell migration through protein kinase Cα (PKCα) activation [101], which can be 
related with the overexpression of mTOR in cases with distant metastases that we found 
in our results.  
A previous study in thyroid tumors reported an overexpression of Sin1, a 
component of mTORC2, and phosphorylated Akt (p-Akt) on Ser473 in aggressive variants 
of PTC compared to cPTC [132]. In other models, mTORC2 seems to be associated with 
characteristics of aggressiveness, invasion and poor prognosis. This complex has been 
implicated in bladder cancer as being critical for its invasive behavior, as seen in cell lines 
and tissue specimens [133]; in colorectal cancer, Gulhati et al. [134] observed an 
overexpression of mTORC2 in tissue specimens and an association of that expression 
with invasion and migration in cell lines; in gliomas [135] it has also been reported an 
increase in mTORC2 activity in cell lines and tissue specimens, correlating with increased 
levels of rictor, which translates into proliferation of tumor cells and invasive potential; in 
erbB2-positive breast cancer, the authors detected high expression of p-Akt (Ser473) 
associated with metastases in tumor cells [136]. Furthermore, mTORC2 seems to be a 
central player in cancer cell metabolism, with probable effect on epigenetics [137, 138]. 
 
 
mTOR PATHWAY AND GENETIC ALTERATIONS 
 
Regarding genetic alterations, we did not find p-S6 or p-mTOR expression to be 
associated with the mutational status of the genes that were screened. However, in 
previous studies by Faustino et al. [113] and Ahmed et al. [125], expression of p-S6 and 
p-mTOR was associated with BRAF mutation in PTC. 
Mutations in RAS genes, namely HRAS and KRAS, were also found to be 
associated with higher expression of p-S6 in medullary thyroid carcinoma [128].  
 
 
mTOR PATHWAY AND TREATMENT FOR THYROID CANCER 
 
mTOR inhibitors are classified as rapamycin and rapamycin analogs, such as 
temsirolimus and everolimus. These drugs act by forming a complex with FK506 binding 
protein (FKBP12), and this complex acts as an allosteric inhibitor of mTORC1. The acute 
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inhibition occurs because raptor dissociates from p-mTOR [139]. Recent discoveries 
showed that mTORC2 can also be inhibited after prolonged treatment with rapamycin in a 
subset of cell lines, by dissociation of rictor from the complex, and inhibition of Akt 
phosphorylation on Ser473 [140]. This mTORC2 inhibition was also observed in different 
tissues of mice, with decreased expression of PKCα Ser657 and Akt Ser473 [141]. 
 Several studies have been performed to evaluate mTOR inhibitors in aggressive 
forms of cancer, namely in treatment-refractory metastatic pancreatic cancer [142], 
treatment-refractory metastatic renal cell carcinoma [143], recurrent Hodgkin lymphoma 
[144], recurrent aggressive lymphoma [145], recurrent/metastatic breast cancer [146], 
recurrent/metastatic endometrial cancer [147] and recurrent/refractory mantle cell 
lymphoma [148]. While they seemed promising at first, increasing the time to tumor 
progression, their effect was short-lasting, but effective in the breast cancer study, due to 
development of therapy resistance after failure to inhibit mTORC2.  
The second-generation of mTOR inhibitors are aimed to inhibit both complexes, by 
binding to the ATP-binding site of mTOR and interfering with some of its effectors. They 
became important because rapamycin inhibits preferentially mTORC1, while mTORC2 
continues to phosphorylate Akt and maintaining the pathway active – a mechanism of 
resistance to rapamycin. They have been shown to surpass rapamycin and its analogs’ 
inhibition potential. Torin1 and Torin2, two of those inhibitors tested in vitro and in vivo, 
showed a decrease in tumor size and cell viability, as well as inactivation of the effectors 
S6, 4E-BP1 and Akt [125, 149]. So far, these drugs have not been approved for 
therapeutic purposes. 
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CONCLUSIONS 
 
We confirm activation of the mTOR pathway in PTC. We report an association 
between expression of p-mTOR and aggressive features, such as distant metastases and 
extrathyroid extension. Being highly expressed in aggressive PTC, p-mTOR would be 
useful to evaluate behavior in these tumors. Furthermore, p-mTOR was located in the 
periphery and invasive front of tumors, as well as in the membrane in the majority of 
cases.  
Expression of p-S6 was not consistent between series, showing to be associated 
with both good prognosis and vascular invasion. We feel that p-S6 is not a robust marker 
to evaluate the outcome in PTC. 
Given our results, we hypothesize that activation of the mTOR pathway in PTC 
occurs via phosphorylation of mTORC2. 
  
 
  
 
FUTURE PERSPECTIVES  
  
In light of our results, we should further investigate the lack of correspondence 
between p-mTOR and p-S6 in thyroid tumors, studying, for example, mTORC2 
downstream effectors, such as p-Akt Ser473 in tumor samples as an mTORC2 activation 
readout. Additionally, in vitro studies would be performed with thyroid cancer cell lines. We 
intend to evaluate their response to treatment with rapamycin, taking into account different 
genetic backgrounds, as well as markers for the activation of the PI3K/Akt/mTOR pathway 
– such as mTOR, S6, Akt. NIS will also be evaluated in cell lines.  
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SUPPLEMENTARY TABLES 
 
Table 1 – Cases with missing information within the whole series (n=90), in PTC (n=73) and in FTC (n=13) in Series 1 
 
 
Table 2 – Cases with missing information within cPTC (n=39) and fvPTC (n=23) in Series 1 
Variables 
All cases 
(n=90) 
PTC 
(n=73) 
FTC 
(n=13) 
Age 
(%) 
1 
(1.1) 
1 
(1.4) 
- 
Gender 
(%) 
1 
(1.1) 
1 
(1.4) 
- 
Tumor size 
(%) 
1 
(1.1) 
1 
(1.4) 
- 
Tumor capsule 
(%) 
2 
(2.2) 
2 
(2.7) 
- 
Tumor capsule invasion 
(%) 
3 
(5.7) 
1 
(2.6) 
2 
(15.4) 
Multifocality 
(%) 
2 
(2.2) 
2 
(2.7) 
- 
Vascular invasion 
(%) 
- - - 
Lymph node metastasis 
(%) 
15 
(16.7) 
11 
(15.1) 
3 
(23.1) 
Extrathyroid extension 
(%) 
4 
(4.4) 
4 
(5.5) 
- 
Lymphocytic infiltrate 
(%) 
3 
(3.3) 
1 
(1.4) 
2 
(15.4) 
TERT promoter mutation 
(%) 
- - 
1 
(7.7) 
NRAS mutation 
(%) 
- - 
1 
(7.7) 
BRAF mutation 
(%) 
- - 
1 
(7.7) 
PAX8/PPARγ  rearrangement 
(%) 
1 
(1.1) 
1 
(1.4) 
1 
(7.7) 
RET/PTC rearrangement 
(%) 
- - 
1 
(7.7) 
Staging 
(%) 
6 
(6.7) 
5 
(6.8) 
- 
Variables 
cPTC 
(n=39) 
fvPTC 
(n=23) 
Age 
(%) 
- 
1 
(4.3) 
Gender 
(%) 
- 
1 
(4.3) 
Tumor size 
(%) 
1 
(2.6) 
- 
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Table 3 – Distribution of p-S6 scores in each variant of PTC (n=73) in Series 1 
Score cPTC fvPTC sPTC tcPTC oPTC stPTC mixed PTC 
0 11 3 2 0 0 0 1 
1 4 4 0 0 1 0 0 
2 5 0 0 0 0 0 2 
3 4 1 0 0 0 0 0 
4 5 3 0 1 0 1 0 
6 3 5 0 0 0 0 1 
8 2 2 0 0 0 0 0 
9 2 2 1 0 0 0 1 
12 3 3 0 0 0 0 0 
Total 39 23 3 1 1 1 5 
 
 
Table 4 – Distribution of p-mTOR scores in each variant of PTC (n=73) in Series 1 
Score cPTC fvPTC sPTC tcPTC oPTC stPTC mixed PTC 
0 2 3 0 0 0 0 0 
1 1 2 0 0 0 0 0 
2 1 2 1 0 0 0 0 
3 2 2 0 0 0 0 0 
Tumor capsule 
(%) 
1 
(2.6) 
1 
(4.3) 
Tumor capsule invasion 
(%) 
- 
1 
(7.7) 
Multifocality 
(%) 
2 
(5.1) 
- 
Vascular invasion 
(%) 
- - 
Lymph node metastasis 
(%) 
6 
(15.4) 
4 
(17.4) 
Extrathyroid extension 
(%) 
1 
(2.6) 
2 
(8.7) 
Lymphocytic infiltrate 
(%) 
- 
1 
(4.3) 
TERT promoter 
(%) 
- - 
NRAS 
(%) 
- - 
BRAF 
(%) 
- - 
PAX8/PPARγ  
(%) 
1 
(2.6) 
- 
RET/PTC 
(%) 
- - 
Staging 
(%) 
 1 
(2.6) 
3 
(13) 
Role of mTOR Pathway in Differentiated Thyroid Cancer                                                                                                                  MSc in Oncology Thesis Dissertation 
 82 
4 5 2 0 0 0 1 0 
6 10 1 1 0 0 0 1 
9 6 3 0 1 0 0 1 
12 12 8 1 0 1 0 3 
Total 39 23 3 1 1 1 5 
 
 
Table 5 – Cases with missing information within the whole series (n=127), in PTC (n=114) and in FTC (n=6) in Series 2 
Variables All cases (n=127) PTC (n=114) FTC (n=6) 
Age 
(%) 
1 
(0.8) 
- - 
Gender 
(%) 
- 
1 
(0.9) 
- 
Lymph node metastases 
(%) 
1 
(0.8) 
1 
(0.9) 
- 
Distant metastases 
(%) 
1 
(0.8) 
1 
(0.9) 
- 
Tumor size 
(%) 
10 
(7.9) 
6 
(5.3) 
2 
(33.3) 
Tumor capsule  
(%) 
7 
(5.5) 
4 
(3.5) 
1 
(16.7) 
Vascular invasion 
(%) 
10 
(7.9) 
9 
(6.1) 
1 
(16.7) 
Tumor margins 
(%) 
7 
(5.5) 
4 
(3.5) 
1 
(16.7) 
Thyroid capsule invasion 
(%) 
11 
(8.7) 
7 
(6.1) 
1 
(16.7) 
Extrathyroid extension 
(%) 
8 
(6.3) 
4 
(3.5) 
1 
(16.7) 
Multifocality 
(%) 
9 
(7.1) 
6 
(5.3) 
1 
(16.7) 
Lymphocytic infiltrate 
(%) 
10 
(7.9) 
7 
(6.1) 
2 
(33.3) 
Staging 
(%) 
9 
(7.1) 
6 
(5.3) 
1 
(16.7) 
TERT promoter mutation 
(%) 
26 
(20.5) 
24 
(21.1) 
2 
(33.3) 
NRAS mutation 
(%) 
16 
(12.6) 
14 
(12.3) 
2 
(33.3) 
BRAF mutation 
(%) 
4 
(3.1) 
4 
(3.5) 
- 
One year disease free survival 
(%) 
4 
(3.1) 
4 
(3.5) 
1 
(16.7) 
Evidence of disease during follow-up  
(%) 
- - 
1 
(16.7) 
Number of 131I therapies 
(%) 
4 
(3.1) 
4 
(3.5) 
- 
Cumulative dose 
(%) 
5 
(3.9) 
5 
(4.4) 
- 
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Table 6 – Cases with missing information within cPTC (n=77) and in fvPTC (n=28) in Series 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease free survival after follow-up 
(%) 
3 
(2.4) 
3 
(2.6) 
- 
Variables cPTC (n=77) fvPTC (n=28) 
Tumor size 
(%) 
6 
(7.8) 
- 
Tumor capsule  
(%) 
4 
(5.2) 
- 
Vascular invasion 
(%) 
6 
(7.8) 
1 
(3.6) 
Tumor margins 
(%) 
4 
(5.2) 
- 
Thyroid capsule invasion 
(%) 
6 
(7.8) 
1 
(3.6) 
Extrathyroid extension 
(%) 
4 
(5.2) 
- 
Multifocality 
(%) 
5 
(6.5) 
- 
Lymphocytic infiltrate 
(%) 
6 
(7.8) 
1 
(3.6) 
Staging 
(%) 
4 
(5.2) 
1 
(3.6) 
TERT promoter mutation 
(%) 
15 
(19.5) 
5 
(17.9) 
NRAS mutation 
(%) 
- 
5 
(17.9) 
BRAF mutation 
(%) 
2 
(2.6) 
2 
(7.1) 
One year disease free survival 
(%) 
3 
(3.9) 
- 
Number of 131I therapies 
(%) 
2 
(2.6) 
- 
Cumulative dose 
(%) 
3 
(3.9) 
- 
Disease free survival after follow-up 
(%) 
2 
(2.6) 
- 
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Table 7 – Distribution of p-S6 scores in each variant of PTC (n=76) in Series 2 
Score cPTC fvPTC sPTC oPTC wPTC 
0 25 7 0 1 1 
1 8 2 1 0 1 
2 7 4 0 0 0 
3 3 3 1 0 0 
4 2 0 1 0 0 
6 3 1 1 0 0 
9 1 1 0 0 0 
12 2 0 0 0 0 
Total 51 18 4 1 2 
 
 
Table 8 – Distribution of p-mTOR scores in each variant of PTC (n=107) in Series 2 
Score cPTC fvPTC sPTC oPTC tcPTC wPTC 
0 23 8 0 0 1 1 
1 7 0 0 0 0 0 
2 11 3 1 0 0 0 
3 3 3 2 0 0 0 
4 6 3 0 0 0 0 
6 7 2 0 0 0 0 
8 1 1 1 0 0 0 
9 7 3 0 0 0 1 
12 8 2 0 0 0 1 
Total 73 25 4 1 1 3 
 
 
Table 9 – Correlation between p-S6 and p-mTOR in Series 1 
 All cases (n=90) PTC (n=73) cPTC (n=39) fvPTC (n=23) 
P-value 0.680 0.962 0.528 0.967 
Pearson 
Correlation 0.044 -0.006 0.104 -0.009 
 
 
Table 10 – Correlation between p-S6 and p-mTOR in Series 2 
 All cases (n=127) PTC (n=114) cPTC (n=77) fvPTC (n=28) 
P-value 0.988 0.753 0.700 0.360 
Pearson 
Correlation -0.002 -0.038 -0.057 0.237 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Representative case of the 
excluded cases from Series 2. This case is a 
cPTC with cancer cells surrounding the follicles 
and lymphocytes infiltrating the tissue (200x 
magnification).  
Figure 1 – Positive controls. The tissue used as a positive control is a lymph node invaded by 
cancer cells. We can see in a brown coloration the cells stained for the marker and in blue the 
lymphocytes (200x magnification). A – p-S6 ; B – p-mTOR. 
A B 
A B 
Figure 3 – Staining of p-S6. p-S6 shows a preferential cytoplasmic localization (brown 
coloration) in tumor cells. A – cPTC from Series 2; B – fvPTC from Series 1 (200x 
magnification). 
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A B 
Figure 4 – Representative image of p-mTOR staining. p-mTOR was localized both in 
cytoplasm and membrane of tumor cells (brown coloration). A – Warthin like PTC from Series 2; 
B – cPTC from Series 1 (200x magnification). 
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